Korean Small-Caps on Korea Invest Insights

Pamicell (005690) Part 3 — 1Q26 Earnings Confirmation: Revenue ₩36.7bn, OP ₩13.1bn, OPM 35.7%. Above Consensus on All Lines

Tue, 12 May 2026 11:30:00 +0900

📚 Pamicell series — Part 3. Part 1: Pamicell — April Foreign + Institutional Buying and Doosan Electro BG AI CCL Materials Re-rating Part 2: Pamicell Part 2 — AI CCL Materials Transition and the 12-24 Month Industry Cycle

🔗 Related reading: ROE-25% Screen — 4 Names That Pass 9 Filters · Korea AI PCB Ecosystem: 10 Companies · Why Korea Part 1 — Semiconductor Substrates

Parts 1 and 2 traced Pamicell’s reclassification from a biochemicals company into an AI-memory CCL (copper-clad-laminate) upstream materials supplier. KRX officially changed the industry code from “basic-pharmaceutical manufacturing” to “electronic-components manufacturing” on May 4. Citi and Goldman Sachs reframed the CCL supply shortage as a 2026-2027 “new normal.” On May 12, the 1Q26 print landed — revenue ₩36.7bn (vs. ₩33.1bn consensus), OP ₩13.1bn (vs. ₩10.6bn consensus), OPM 35.7%. This is the first numerical confirmation of the Parts 1 / 2 thesis.

TL;DR

1Q OP ₩13.1bn cleared consensus (₩10.6bn) by +23.6%. Revenue ₩36.7bn also +10.9% above consensus ₩33.1bn. OPM 35.7%, with revenue up +43.4% QoQ (₩25.6bn → ₩36.7bn).
The revenue range broke out. Four straight quarters (1Q25-4Q25) printed revenue in the ₩21.5-27.0bn band. 1Q26 printed ₩36.7bn — clearing the box top by ~₩10bn.
OPM stepped up from 30-32% to 35.7%. Pure volume growth would have produced flat margin; revenue and margin lifting together signals a mix shift toward higher-value products (low-dielectric materials).
The 2026 ₩60bn+ OP scenario requires 2Q-4Q quarterly OP averaging ₩15.0bn+. The 1Q ₩13.1bn print clears the “necessary condition,” not the “sufficient condition.”
TTM PER sits in the 23-30× band. Not “extremely cheap” by Korean-market standards, not “extremely expensive” either. Multiple-validation depends on whether the 2026-2027 forward path holds.

1. 1Q26 print — how far above estimates

1.1 Vs. consensus

Item	Actual	Consensus	Diff	Read
Revenue	₩36.7bn	₩33.1bn	+10.9%	Beat
OP	₩13.1bn	₩10.6bn	+23.6%	Strong beat
NI	₩11.7bn	₩11.7bn	+0.1%	In-line
OPM	35.7%	32.0%	+3.7pp	Core positive
NPM	31.9%	35.3%	-3.4pp	NPM softer than expected

Cross-checks:

Revenue beat = 36.7 / 33.1 - 1 = +10.9% ✓
OP beat = 13.1 / 10.6 - 1 = +23.6% ✓
OPM = 13.1 / 36.7 = 35.7% ✓
NPM = 11.7 / 36.7 = 31.9% ✓
Expected OPM = 10.6 / 33.1 = 32.0% ✓

1.2 Quarterly trajectory — the box top broke

Period	Revenue	OP	NI	OPM	NPM
1Q25	₩21.5bn	₩3.1bn	₩4.2bn	14.4%	19.5%
2Q25	₩27.0bn	₩8.4bn	₩8.5bn	31.1%	31.5%
3Q25	₩26.8bn	₩8.2bn	₩7.4bn	30.6%	27.6%
4Q25	₩25.6bn	₩8.1bn	₩8.8bn	31.6%	34.4%
1Q26	₩36.7bn	₩13.1bn	₩11.7bn	35.7%	31.9%

YoY / QoQ:

Revenue YoY = 36.7 / 21.5 - 1 = +70.7%
OP YoY = 13.1 / 3.1 - 1 = +322.6%
NI YoY = 11.7 / 4.2 - 1 = +178.6%
Revenue QoQ = 36.7 / 25.6 - 1 = +43.4%
OP QoQ = 13.1 / 8.1 - 1 = +61.7%
NI QoQ = 11.7 / 8.8 - 1 = +33.0%

This isn’t a “modest beat.” Revenue stepped up from the ₩25-27bn band to ₩36.7bn — a clear range break. And OPM lifted from a ~30-32% range to 35.7%, with revenue and margin moving up together — a pattern that volume growth alone does not produce.

2. How far do Parts 1 / 2 theses get validated

2.1 Part 1 — Doosan Electro BG AI CCL cycle exposure

Part 1 framed Pamicell not as a biochemical company but as an AI-memory CCL (copper-clad-laminate) upstream materials supplier. The chain: Doosan Electro BG grows AI-memory / server-grade high-value CCL revenue → upstream low-dielectric materials suppliers (Pamicell) capture the lift.

How the 1Q26 print is consistent with that read:

Revenue jumped from ~₩25.6bn (4Q25) to ₩36.7bn (+43% QoQ) — too large to be pure price effect, suggesting volume growth
OPM 35.7% — high-margin product-mix lift signal
Part 2 noted that Doosan Electro BG’s 1Q26 OPM (30.1%) precisely matched Pamicell’s 2025 average OPM (30.1%). This quarter, Pamicell extended that linkage by stepping one tier higher (35.7%).

2.2 Part 2 — the “new normal” industry-cycle framing

Part 2 catalogued five data points by early May:

KRX industry-code change on May 4 (basic-pharmaceutical → electronic-components)
Citi / Goldman Sachs’ “CCL supply shortage as 2026-2027 new normal” call
DS Investment + Meritz Securities 1Q26 estimate convergence (revenue ₩36.2bn, OP ₩12.1bn, OPM 33%)
Expanded 4-layer value chain (upstream mineral → monomer → polymer → CCL application)
Doosan Electro BG OPM linkage to Pamicell

Today’s actual print (revenue ₩36.7bn, OP ₩13.1bn, OPM 35.7%) cleared the DS / Meritz estimate (revenue ₩36.2bn, OP ₩12.1bn, OPM 33%) by +1% revenue, +8% OP, +2.7pp OPM. The “new normal” thesis just got one quarter of numerical confirmation.

3. What it takes to justify ₩60bn+ FY26 OP

3.1 Simple 4× annualization

Annualized revenue = 36.7 × 4 = ₩146.8bn
Annualized OP = 13.1 × 4 = ₩52.4bn
Annualized NI = 11.7 × 4 = ₩46.8bn

At a market cap of ₩1,102.5bn:

Annualized PER = 1,102.5 / 46.8 = 23.6×
Annualized EV/OP-proxy = 1,102.5 / 52.4 = 21.0×

That isn’t extreme by Korean-market standards. But the published market read of ₩56-63bn FY26 OP requires more than 1Q ₩13.1bn × 4.

3.2 The remaining 3 quarters

FY26 OP target	1Q actual	Remaining OP	2Q-4Q avg required
₩56.2bn	₩13.1bn	₩43.1bn	₩14.4bn
₩57.7bn	₩13.1bn	₩44.6bn	₩14.9bn
₩60.5bn	₩13.1bn	₩47.4bn	₩15.8bn
₩63.3bn	₩13.1bn	₩50.2bn	₩16.7bn

Cross-check:

₩60bn target - 1Q ₩13.1bn = ₩46.9bn / 3 = ₩15.6bn
₩60.5bn target - 1Q ₩13.1bn = ₩47.4bn / 3 = ₩15.8bn ✓

In other words: for FY26 OP ₩60bn+ to feel natural, quarterly OP from 2Q onward needs to step up to ~₩15-16bn. The 1Q ₩13.1bn print is the starting point, not the destination.

4. TTM (trailing 12-month) — two ways to calculate

4.1 Why two paths exist

The official quarterly filings include quarterly P&L. But company IR materials’ FY25 annual figures don’t always reconcile to a clean sum of the four quarters. With the user-shared quarterly data:

FY25 quarterly sum:
Revenue = 21.5 + 27.0 + 26.8 + 25.6 = ₩100.9bn
OP = 3.1 + 8.4 + 8.2 + 8.1 = ₩27.8bn
NI = 4.2 + 8.5 + 7.4 + 8.8 = ₩28.9bn

The Part 1 / 2 analysis used company IR FY25 annuals of revenue ₩114.0bn, OP ₩34.3bn, NI ₩40.3bn. Gaps: revenue ₩13bn, OP ₩6.5bn, NI ₩11.4bn. These can arise from (a) standalone vs. consolidated, (b) continuing vs. discontinued operations, (c) cumulative vs. quarterly conversion, (d) reclassification of operating vs. non-operating items. Definitive reconciliation requires reading the actual quarterly report income statement.

4.2 TTM under both bases

(A) Quarterly-sum basis (conservative)

TTM revenue = 27.0 + 26.8 + 25.6 + 36.7 = ₩109.1bn
TTM OP = 8.4 + 8.2 + 8.1 + 13.1 = ₩37.8bn
TTM NI = 8.5 + 7.4 + 8.8 + 11.7 = ₩36.4bn
TTM PER = 1,102.5 / 36.4 = 30.3×
TTM mcap / OP = 1,102.5 / 37.8 = 29.2×

(B) IR-annual-adjusted basis

TTM revenue = 114.0 - 21.5 + 36.7 = ₩129.2bn
TTM OP = 34.3 - 3.1 + 13.1 = ₩44.3bn
TTM NI = 40.3 - 4.2 + 11.7 = ₩47.8bn
TTM PER = 1,102.5 / 47.8 = 23.1×
TTM mcap / OP = 1,102.5 / 44.3 = 24.9×

Both readings converge on the same conclusion: TTM PER 23-30× — not “extremely cheap” by Korean-market standards, not “extremely expensive” either. Multiple-validation rests on the 2026-2027 forward path holding. One quarter doesn’t settle the question.

5. What’s validated, what remains open

5.1 Validated by 1Q26

Item	Part 1 / 2 expectation	1Q26 actual	Result
1Q revenue	₩35.0-36.2bn	₩36.7bn	Above top of range
1Q OP	₩11.5-12.3bn	₩13.1bn	Above top of range
1Q OPM	~33%	35.7%	One tier higher
Range break	Jump from ₩25.6bn (4Q25)	₩36.7bn	Confirmed

5.2 Still open

Item	Part 1 / 2 expectation	Check window	If not confirmed
2Q-4Q revenue ₩40bn+	FY26 revenue ₩160bn+	2Q report (late Jul-early Aug)	1Q-as-one-off concern
2Q-4Q OP ₩15bn+	FY26 OP ₩60bn+	2Q report	Multiple-rerating gets harder
Doosan Electro BG high-value CCL revenue visibility	New-normal cycle validation	Doosan quarterly IR	Single-customer concentration risk surfaces
Disclosure of low-dielectric materials revenue mix	Quantification of mix shift	Quarterly report / IR Q&A	OPM 35.7% remains under-attributed
PTFE competitor qualification / dual sourcing (bear signal)	Maintained supply position	Industry news	Core Parts 1 / 2 thesis damage

6. Key calendar — what to verify next

Window	Event	Why it matters
Throughout 2Q	Doosan Electro BG 2Q26 guidance	Pamicell’s primary end-demand pulse
June-July	Sell-side estimate revisions	Does the FY26 ₩60bn OP scenario enter consensus
Late July / early August	Pamicell 2Q26 print	Confirms or denies the 2Q-4Q ₩40bn+/₩15bn+ path
2H	Post-reclassification flow effect	How the “basic-pharma → electronics” code change reroutes index / theme flows
Ongoing	PTFE competitor qualification news	If it materializes, Parts 1 / 2 thesis takes damage

7. Bottom line

The Pamicell 1Q26 print is the first numerical validation of the Parts 1 / 2 thesis — Pamicell reclassifying from a biochemicals name into an AI-memory CCL upstream materials supplier. Revenue ₩36.7bn broke the ₩21.5-27.0bn range; OPM lifted from ~30-32% to 35.7%; OP ₩13.1bn cleared consensus ₩10.6bn by +23.6%.

But a single quarter does not settle FY26. For the ₩60bn+ OP scenario to feel natural, 2Q-4Q quarterly OP needs to step to ~₩15-16bn. That answer lands in the late-July / early-August 2Q report.

Part 1 introduced the AI-CCL upstream reclassification hypothesis. Part 2 tracked five data points showing the cycle as a 12-24 month new normal. Part 3 logs the first numerical clearance of that thesis. Validation remains in progress, and the next quarterly print is what distinguishes “single-quarter spike” from “sustained cycle.”

FAQ

Q: Is OP ₩13.1bn a strong number? A: It’s +23.6% above the ₩10.6bn consensus and lifts OPM to 35.7% — one tier above the prior quarter’s 31.6%. Revenue also rose +43% QoQ from ₩25.6bn to ₩36.7bn. This qualifies as a strong beat, with the caveat that it’s a single quarter.

Q: Why did NI come in exactly in-line while OP beat strongly? A: Most likely larger-than-expected non-operating expense or tax. Definitive attribution requires the quarterly-report income statement. The OPM 35.7% itself signals operating fundamentals strengthening regardless.

Q: What drove the revenue jump to ₩36.7bn? A: The Part 1 / 2 working hypothesis is Doosan Electro BG’s AI-memory high-value CCL revenue growth flowing upstream into low-dielectric materials. The company does not disclose customer-level revenue, so direct verification isn’t possible. The Part 2 observation that Doosan Electro BG’s 1Q26 OPM (30.1%) tracked Pamicell’s 2025 average OPM (30.1%) provides an indirect signal of the linkage.

Q: Is TTM PER 23-30× expensive or cheap? A: Neither extreme by Korean-market standards. The multiple’s adequacy depends on whether FY26 OP reaches the ₩60bn band — in that case, the FY26 forward PER drops to 17-20×.

Q: What invalidates the Parts 1 / 2 thesis? A: Three primary breaks: (1) 2Q-4Q revenue reverting to the ₩25-30bn range (one-off interpretation); (2) PTFE competitor qualification formalizing dual sourcing (supply-position erosion); (3) Doosan Electro BG AI CCL guidance weakening (demand-pulse erosion). Any one materializing would meaningfully weaken Parts 1 / 2.

Q: What does the KRX industry-code change do? A: As of May 4, classification moved from “basic-pharmaceutical manufacturing” to “electronic-components manufacturing.” Index / theme classification and flow patterns can shift accordingly. Underlying fundamentals don’t change because of the code change itself.

Q: How do you track Pamicell’s customer-level revenue without disclosure? A: Indirect routes: (1) Doosan Electro BG’s quarterly IR for CCL revenue / mix commentary, (2) the Pamicell quarterly report body for any explicit low-dielectric-materials mix mention, (3) industry news flow on memory / server CCL supply tightness.

This article is for research and informational purposes only and does not constitute investment advice. 1Q26 figures are based on user-shared DART preliminary results (2026-05-12 10:27 KST); the full quarterly report body is not directly verified. Consensus figures (revenue ₩33.1bn / OP ₩10.6bn / NI ₩11.7bn) are user-shared. FY25 annual figures referenced in Part 1 / 2 (revenue ₩114.0bn / OP ₩34.3bn) differ from the quarterly-sum baseline (₩100.9bn / ₩27.8bn); both bases are calculated in section 4. Doosan Electro BG-level revenue, low-dielectric-materials mix, and PTFE competitor qualification status are not precisely verifiable from public sources. Analysis can be wrong. Data cut: May 12, 2026 KST.

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

KOSDAQ Series Part 2 — Screening for Quality with ROE: 1,820 → 105 → 35 → 6. The 0.3% That Combines High ROE, Margin, Growth, and Flow

Sun, 10 May 2026 22:30:00 +0900

📚 KOSDAQ Series — Part 2. Part 1: KOSDAQ Complete Guide for Foreign Investors — 1,820 Companies, October 2026 Promotion / Relegation Reform

KOSDAQ’s promotion-relegation reform launches in October 2026. Only 100 of ~1,820 listed companies enter the Premium tier. The criteria are financial soundness, growth, and governance. That’s screen-able now. The wide net (ROE ≥15%, OP growth positive) returns 105 candidates. The tight net (ROE ≥25%, daily turnover ≥₩1bn) returns 35. Layering ROE + operating margin + earnings growth + foreign-and-institutional flow as 4 simultaneous filters compresses to 6 names. 1,820 → 105 → 35 → 6 — the final candidate set is 0.3% of the listed universe. The real alpha in this reform is not owning KOSDAQ broadly. It is the separation between names institutions can buy and names they cannot.

TL;DR

The 2-stage funnel: 105 → 35 → 6. Filter 1 (ROE ≥15%, OP growth positive) clears 105 of KOSDAQ’s ~1,820 names. Filter 2 (ROE ≥25%, ₩1bn daily turnover) cuts to 35. The intersection of high ROE, high margin, growth, and constructive flow narrows to 6 names — 0.3% of the universe.
Three different shapes — growth, margin, value. Silicon2 (ROE 47%, margin 18%, PER 15×) for balanced growth. Classys (ROE 26%, margin 51%, PER 27×) for highest-quality margins. Easy Bio (ROE 29%, PER 7×) for value.
The real alpha is in classification, not the list itself. The 2022 KOSDAQ Global Index proved curation works (+160% vs. broad +65%). It also proved that a “good list” without ETF / NPS / institutional plumbing doesn’t move money. The October reform is designed to fix the second part — Premium ETFs, NPS benchmark inclusion, and the People’s Growth Fund are the three explicit channels.
There are losers from the reform too. If Premium criteria are earnings-based, large-cap-but-loss-making names — Ecopro BM at PER ~596×, ABL Bio at -₩48.6bn, Robotis at PER ~390× — risk exclusion. Falling out of Premium means losing institutional and passive flow, which is a negative alpha vector worth tracking on the short side.
Don’t buy KOSDAQ. Separate it. The investment substance of the reform is identifying which KOSDAQ names institutions will be forced to own and which will lose their pseudo-benchmark status.

1. Why ROE matters — Premium-tier inclusion logic

1.1 The Premium tier’s selection criteria

Part 1 covered the headline framework: Premium (Tier 1) holds ≤100 names selected on financial soundness, growth, and governance. Final criteria are still being calibrated, but the existing KOSDAQ Global Segment requirements offer a useful prior:

Market cap ≥₩500bn or top 7%
Operating profit ≥₩30bn OR revenue ≥₩300bn
Corporate-governance rating ≥B
Financial-health and disclosure-quality requirements

Premium will likely be tighter than this. The design intent is “names that actually earn money,” not “names with large caps alone.”

1.2 Why ROE is the right starting filter

ROE measures how efficiently equity capital generates earnings. High ROE = the business uses small capital to produce large profit.

For Premium-inclusion screening, ROE works because:

High ROE:
→ Business has an earnings base (loss-making companies have meaningless ROE)
→ Capital efficiency — exactly what pension funds underwrite
→ Compatible with both growth and quality screens

Low ROE:
→ Either no earnings, or capital base too large relative to earnings
→ Pension capital can't easily be deployed
→ Lower probability of Premium inclusion

1.3 What the KOSDAQ Global Index already proved

KOSDAQ Global Index (\~50 quality names):
2022.11.21 inception (1,000) → 2026.05.08 (2,602) → +160.2%

Broader benchmarks (same period):
KOSDAQ broad: +65%
KOSDAQ 150: +93%
KOSDAQ Global: +160%

Annualized:
KOSDAQ Global: \~31.8% CAGR
KOSDAQ 150: \~20.9% CAGR
KOSDAQ broad: \~15.6% CAGR

Verification: Global CAGR = (2,602 / 1,000)^(1/3.46) - 1 = 31.8% ✓

The asset class isn’t the problem. Selection is. The Premium reform institutionalizes selection. For investors, the alpha lies in identifying probable-Premium names before the list is published.

2. The 2-stage funnel — wide net to tight net

2.1 Filter 1 — ROE ≥15% + positive OP growth

Start with the widest defensible net.

Filter 1 conditions:
- ROE ≥15%
- OP growth YoY positive
- OP positive (no losses)
- No liquidity / flow / PER constraints applied

(Financial cut: 2026-05-07. Price / flow cut: 2026-05-08.)

Group	Names passing
All Korean listed	173
KOSDAQ	105
KOSPI	68

105 of KOSDAQ’s ~1,820 names clear Filter 1 — about 5.8%. That’s the size of the universe of profitable, growing, high-ROE businesses on the small-cap board.

The top 27 of the 105, sorted by ROE:

Name	Ticker	ROE	OP growth	OP margin	PER	20D price	20D F+I net buy
Sunic System	171090	101.5%	+1,311%	21.6%	5.2×	+7%	-₩39.6bn
Hanpass	408470	94.2%	+58%	12.4%	—	-22%	-₩5.5bn
Genic	123330	59.8%	+150%	19.1%	7.0×	-14%	-₩14.6bn
JTC	950170	57.4%	+117%	15.4%	3.3×	+7%	+₩0.3bn
S-Connect	096630	49.8%	+27%	4.8%	1.3×	+390%	-₩1.1bn
Silicon2	257720	46.9%	+49%	18.4%	14.8×	+9%	+₩58.6bn
Sungho Electronics	043260	46.3%	+21%	3.3%	6.9×	+3%	-₩4.0bn
ITCEN Global	124500	45.9%	+378%	3.2%	15.1×	+20%	-₩6.7bn
BHI	083650	44.4%	+245%	9.8%	24.8×	0%	-₩141.4bn
SM Entertainment	041510	41.6%	+110%	15.6%	8.9×	+6%	-₩0.9bn
Inca Financial Service	211050	39.7%	+10%	9.3%	9.1×	-12%	₩0bn
Alteogen	196170	39.4%	+321%	49.5%	170.7×	-9%	+₩20.6bn
Wooone Construction	046940	36.8%	+2,300%	17.9%	1.3×	+23%	-₩2.1bn
Inzisoft	100030	35.1%	+109%	12.4%	3.1×	+17%	₩0bn
Dong-Ah Eltec	088130	33.6%	+670%	19.4%	1.4×	+41%	-₩12.7bn
KONA I	052400	32.6%	+166%	28.8%	8.9×	+7%	+₩7.5bn
KNJ	272110	30.8%	+57%	26.3%	6.8×	+11%	-₩0.9bn
Easy Bio	353810	29.1%	+39%	9.4%	7.0×	+4%	+₩1.7bn
Global Tax Free	204620	27.8%	+34%	18.8%	9.1×	+20%	+₩6.4bn
Mico	059090	27.2%	+7%	10.3%	15.2×	+72%	+₩29.4bn
PharmaResearch	214450	26.9%	+70%	40.0%	28.4×	+16%	-₩21.9bn
Classys	214150	26.2%	+39%	50.6%	27.1×	+5%	+₩11.2bn
Leeno Industrial	058470	22.4%	+43%	47.5%	30.2×	-4%	-₩80.5bn
Jeju Semiconductor	080220	19.2%	+274%	11.9%	23.0×	+27%	+₩116.0bn
Dawonnexview	323350	20.4%	+208%	15.0%	11.9×	+96%	+₩2.3bn
Vitzro Cell	082920	18.6%	+34%	28.5%	14.0×	+52%	-₩5.0bn
iNet	462980	18.4%	+725%	8.5%	14.7×	-10%	-₩0.1bn

Three things become immediately visible:

One — Filter 1 alone mixes good candidates with traps. S-Connect (+390% over 20 days), Dawonnexview (+96%), Mico (+72%) — already-overheated names. BHI (institutional net sells -₩141.4bn) — money walking out the door. Hanpass (data instability) — newly listed, unreliable record.

Two — high ROE with thin margin is a quality trap. Sungho Electronics (ROE 46.3%, margin 3.3%), ITCEN Global (margin 3.2%), S-Connect (margin 4.8%). Margins this thin disappear at the first environmental change.

Three — Inca Financial Service stands out. ROE 39.7%, PER 9.1×, clean Filter-1 entry. Margin 9.3% and 20D price -12% mean it’s not a market leader. Discussed separately as a “non-AI quality candidate” in §5.

2.2 Filter 2 — ROE ≥25% + ₩1bn daily turnover

Tighten Filter 1’s 105 with two more constraints.

Filter 2 additional conditions:
- ROE ≥25% (up from 15%)
- 20-day average daily turnover ≥₩1bn

This returns 35 names — under 2% of the listed universe.

2.3 Filter 2’s top 10

Name	ROE	Margin	OP growth	PER	PBR
Silicon2	46.9%	18.4%	+49.3%	14.8×	5.5×
Alteogen	39.4%	49.5%	+320.9%	170.7×	54.4×
KONA I	32.6%	28.8%	+166.2%	8.9×	2.5×
KNJ	30.8%	26.3%	+57.4%	6.8×	1.8×
Easy Bio	29.1%	9.4%	+38.9%	7.0×	1.8×
Global Tax Free	27.8%	18.8%	+34.3%	9.1×	2.3×
Mico	27.2%	10.3%	+6.8%	15.2×	3.7×
PharmaResearch	26.9%	40.0%	+70.0%	28.4×	6.8×
Classys	26.2%	50.7%	+39.4%	27.1×	6.4×
VT	25.7%	19.0%	-25.2%	10.2×	2.5×

2.4 Lesson — quality rises with each cut

Funnel by stage:
Total KOSDAQ: 1,820
Filter 1 (ROE ≥15%, OP growth +): 105 (5.8%)
Filter 2 (ROE ≥25%, ₩1bn turnover): 35 (1.9%)
Filter 3 (ROE+margin+growth+flow combined): 6 (0.3%)

1,820 → 105 → 35 → 6. The final investable candidate set is 0.3% of the universe. This is the operational mechanic behind the KOSDAQ Global Index’s 2.5× outperformance — narrow enough selection, applied consistently.

2.5 The five high-ROE traps to avoid

Trap 1 — High ROE with thin margin. Sungho Electronics (ROE 46.3%, margin 3.3%). High ROE looks attractive but earnings quality is low.

Trap 2 — Holding-company accounting. Soulbrain Holdings (ROE 32.1%, PER 1.6×, margin 1.6%). PER 1.6× looks impossibly cheap, but margin 1.6% suggests holdco-accounting structure rather than operating reality.

Trap 3 — Data instability. Hanpass (ROE 94.2%). Newly listed; data history hasn’t stabilized.

Trap 4 — Already overheated. Mico (20D price +71.6%). Flow is constructive but the move is too fast — buying now is chasing.

Trap 5 — Best-in-class quality at unsupportable multiple. Alteogen (ROE 39.4%, margin 49.5%, PER 170.7×). Fundamentally a great business, but the multiple already prices several years of expected growth.

3. The 6 names that pass all four filters

3.1 Silicon2 — most balanced growth

ROE 46.9% / Margin 18.4% / OP growth +49.3% / PER 14.8×
20D F+I net buy: +₩58.6bn
20D price: +9.2%

K-beauty distribution platform — connecting Korean cosmetic brands to overseas channels. The structural advantage is brand-agnostic exposure: with a portfolio of brand mandates rather than a single hero brand, brand-cycle risk is diversified.

ROE 47%, margin 18%, growth +49%, PER 15×, F+I flow strongest in the cohort at +₩58.6bn. Cleanest 4-of-4 simultaneously.

The caveat is that it’s already a known leader — chasing carries setup risk. Watch the 43,000–45,000 won support zone or a confirmed breakout above the prior high.

3.2 Classys — highest-quality margins

ROE 26.2% / Margin 50.7% / OP growth +39.4% / PER 27.1×
20D F+I net buy: +₩11.2bn
20D price: +5.3%

Aesthetic medical-device company. HIFU (high-intensity focused ultrasound) systems plus consumables sold to dermatology clinics globally.

Margin 50.7% is the headline — best-in-class even within the high-ROE cohort. Razor-and-blades structure: device sale + recurring consumable. 2026 estimate ROE 29.4%, PER 19.4× — not particularly stretched for a quality compounder.

Watch around the 55,000-won support zone.

3.3 GlobalTaxFree — cheapest of the high-ROE set

ROE 27.8% / Margin 18.8% / OP growth +34.3% / PER 9.1×
20D F+I net buy: +₩6.4bn
20D price: +20.4%

Tax refund operator for foreign tourists in Korea. As Korea attracts more visitors driven by K-content and K-beauty tourism, the structural revenue pool grows.

ROE 28%, margin 19%, PER 9× — cheapest in the high-ROE cohort. Risk: any softening in tourism / consumption flow can compress the multiple quickly.

3.4 Easy Bio — cheapest high-ROE value play

ROE 29.1% / Margin 9.4% / OP growth +38.9% / PER 7.0×
20D F+I net buy: +₩1.7bn
20D price: +3.5%

Covered in detail across Part 1 and Part 2 of the Easy Bio sequence. 78% of revenue is now feed additives, building a North America M&A platform. Trades at a 50–64% discount to global peers (Phibro 18×, Anpario 15×).

PER 7× with ROE 29% — a rare combination across the entire Korean market. Cheap high-ROE value play, though not a market leader by character. Margin of 9.4% means it isn’t a high-margin business. Premium-inclusion eligibility depends on whether market cap and absolute earnings clear the still-being-finalized criteria.

3.5 KNJ — numbers good, flow not yet engaged

ROE 30.8% / Margin 26.3% / OP growth +57.4% / PER 6.8×
20D F+I net buy: -₩0.9bn
20D price: +10.9%

Semiconductor wet-cleaning / etching equipment. Numbers are excellent — ROE 31%, margin 26%, growth +57%, PER 7×. But foreign + institutional flow at -₩0.9bn means institutions haven’t engaged.

Buy priority is lower until flow inflects. Good numbers without institutional engagement don’t typically move the price meaningfully.

3.6 PharmaResearch — quality good, flow exiting

ROE 26.9% / Margin 40.0% / OP growth +70.0% / PER 28.4×
20D F+I net buy: -₩21.9bn
20D price: +15.8%

Maker of Rejuran (PDRN-based skin regeneration product). Margin 40%, growth +70% — quality is high. But 20D F+I flow at -₩21.9bn means institutions are net sellers. Price went up, institutions sold — a classic “be careful” combination.

4. Where the real alpha lies — at the separation, not the list

4.1 Don’t own KOSDAQ broadly

A “buy KOSDAQ” trade off the reform headline has no alpha. As shown in Part 1, much of the 1,820-name universe is loss-making or theme-driven.

The alpha is in the separation between names institutions can buy and names they cannot:

If included in Premium:
→ Auto-inclusion in dedicated Premium index ETFs
→ Eligible for pension allocations
→ Liquidity uplift, multiple re-rating

If excluded from Premium:
→ Same retail-driven flow regime as before
→ Possible loss of "leader" status
→ Names with cap-only profile (no earnings) may face further derating

4.2 The Premium-reform losers

This is the under-discussed angle. If Premium criteria are earnings-based, large-cap-but-loss-making names that currently sit in KOSDAQ 150 risk Premium exclusion:

Name	Market cap	Estimated 2026E NI	Implied PER	Risk
Ecopro BM	₩23tn+	~tens of ₩bn	~596×	May fail Premium criteria
ABL Bio	#9 by cap	-₩48.6bn (loss)	n/m	May fail earnings criterion
Robotis	₩5tn	~₩10bn	~390×	Cap excessive vs earnings

These aren’t bad businesses. They may have large future growth. But if Premium criteria require current earnings, exclusion would mean loss of institutional and passive-flow access — a negative alpha vector worth tracking on the short side, or at minimum a position-size reduction signal.

4.3 Three tradable angles

Angle 1 — Already-quality names that gain incremental flow. Leeno Industrial, Jusung Engineering, KOSDAQ Global Segment incumbents. Probably included in Premium. But the incremental alpha is limited — quality is already in the multiple.

Leeno’s 1Q26: revenue ₩99.8bn, OP ₩47.3bn, margin 47.4%. Target prices revised up to ₩150,000. High inclusion certainty but a less asymmetric setup than Angle 2.

Angle 2 — Earnings inflection + Premium-inclusion catalyst. Simmtech is the cleanest example. 2025 OP ₩11.9bn → 2026E OP ₩120-150bn — a 10× lift driven by AI server / memory module substrate mix shift. The market currently treats it as a cyclical-substrate recovery name. If 2026 OP exceeds ₩100bn, it becomes a viable Premium-inclusion candidate. Earnings inflection + policy-driven flow = double re-rating.

Angle 3 — Non-AI quality candidates. Inca Financial Service. Insurance distribution (general agency) business: 2025 revenue ₩1.022tn, OP ₩95.2bn, NI ₩71.3bn. 2026 NI target ~₩100bn. The market will likely interpret KOSDAQ reform through an AI / biotech / robotics lens — but if Premium criteria are earnings-and-governance based, profitable non-AI names also qualify. Surprise re-rating optionality.

5. Cross-section — high-ROE candidates × Premium-inclusion probability

5.1 High-ROE names with Premium-inclusion probability

Name	ROE	Premium probability	Reason
Silicon2	46.9%	High	All four (ROE / margin / growth / flow) clean
Classys	26.2%	High	Margin 50%+, stable profitability
Global Tax Free	27.8%	Medium	Cap and earnings size verification needed
Easy Bio	29.1%	Medium → High	Visible 2026 OP at ~₩50bn level should clear
KNJ	30.8%	Medium	Earnings size and cap thresholds need verification
PharmaResearch	26.9%	High	Margin 40%, stable profitability

5.2 Lower-ROE but high Premium probability

ROE under 25% can still clear Premium if absolute earnings and stability are strong:

Leeno Industrial — margin 47%, 1Q26 OP ₩47.3bn. Stable inclusion candidate.
Jusung Engineering — flagship semi-equipment name. Cap and earnings both clear typical thresholds.
SOOP — internet-broadcast platform. Stable profitability.
Simmtech — 2026 OP >₩100bn would clear earnings criterion.
Inca Financial Service — NI ₩70-100bn band. Non-AI quality candidate.

6. Caveats

6.1 Final criteria not yet published

The most important caveat. Final Premium-100 criteria are not yet released. Industry briefings are scheduled for June and finalization for July. This screen is probable-candidate identification, not a confirmed list.

6.2 High ROE has many traps

ROE alone is not enough. Earnings quality (margin), persistence (growth), and market validation (flow) must align. High ROE with 3% margin, holdco accounting, or unstable data history fails the quality test even if ROE numerically clears.

6.3 APR is KOSPI-listed, not KOSDAQ

For the avoidance of doubt — APR (KOSPI 278470) is on KOSPI, not KOSDAQ, and is not a direct beneficiary of the KOSDAQ promotion-relegation reform. Same with Cosmax (KOSPI 192820). Both are well-known Korean beauty names but on the wrong exchange for this reform.

6.4 Premium inclusion ≠ guaranteed price appreciation

If included, passive flow can arrive — but the lesson of the 2022 KOSDAQ Global Index is that the list part is easier than the flow part. Whether ETFs scale, NPS adopts the benchmark, and the People’s Growth Fund actually deploys to KOSDAQ — those determine whether classification translates to multi-year price action. Visible only after October.

7. Practical priority

Priority	Name	Character	Verdict	Trigger
1	Silicon2	High-ROE growth	Pullback buy #1	43,000–45,000 won support OR confirmed new-high breakout
2	Classys	High-margin device	Buy on support	~55,000 won support hold
3	Simmtech	Earnings inflection + Premium catalyst	Buy on confirmation	2Q26 OP path ≥₩50bn confirmed
4	Easy Bio	Cheap high-ROE value	Value candidate	1Q26 OPM ≥9.4% confirmed
5	Leeno Industrial	Stable inclusion candidate	Wait for pullback	15–20% retracement
6	Global Tax Free	Cheap high-ROE	Conditional buy	6,000-won base + sustained turnover

8. Bottom line

The investment substance of the KOSDAQ reform is not “buy KOSDAQ.” It is the separation between names institutions can own and names they cannot.

Premium-100 inclusion isn’t about market cap — it’s about earnings. The wide net (ROE ≥15%, OP growth positive) clears 105 of 1,820 (5.8%). The tight net (ROE ≥25%, ₩1bn turnover) clears 35 (1.9%). The simultaneous-4 (ROE + margin + growth + flow) clears 6 (0.3%). Silicon2 is the most balanced, Classys the highest-margin, Easy Bio the cheapest.

The corollary matters as much as the headline. Names that fail Premium criteria — large-cap-but-loss-making — face institutional and passive-flow loss. That’s a negative alpha angle worth tracking, possibly via reduced position size on cap-heavy thematic names.

Final criteria publish in July. Until then, the candidate list is preliminary. The October launch is when ETF / NPS / People’s Growth Fund deployment begins, and that’s when real flow either validates the curation or proves the 2022 KOSDAQ Global Index lesson all over again. The KOSDAQ Global Index showed selection matters 2.5× more than asset class. The same logic applies to Premium — which names you choose drives everything.

FAQ

Q: Why ROE as the starting filter? A: Premium-tier criteria emphasize “financial soundness and growth.” ROE captures both — it indicates the business has an earnings base and is using capital efficiently. This is exactly the profile pension capital can underwrite. A practical first filter for Premium-eligibility screening.

Q: Why narrow from 105 to just 6 final candidates? A: ROE alone is not enough. Earnings quality (margin), persistence (growth), and market validation (foreign + institutional flow) all need to coincide. The intersection across all four filters is the 0.3% of the universe — and this 0.3% is where the alpha sits.

Q: Why does Alteogen drop out of the final 6 despite having ROE 39%, margin 49%? A: Because PER 170× already prices in multi-year forward growth. “Good business” and “good entry price” are different questions. Alteogen the company is high-quality; Alteogen the entry-level position is not.

Q: Which names are likely to be excluded from Premium? A: Large-cap-but-low-earnings names. Ecopro BM (PER ~596×), ABL Bio (loss-making, -₩48.6bn), Robotis (PER ~390×). Future growth potential aside, current earnings criteria can fail them. Exclusion means losing institutional / passive-flow access — a negative alpha vector.

Q: Why include Simmtech in the watchlist if it’s not in the final 6? A: Simmtech’s 2026 OP forecast ₩120-150bn is a 10× jump from 2025 ₩11.9bn driven by AI server / memory module substrate mix. The market still treats it as cyclical recovery. If OP clears ₩100bn, it becomes Premium-eligible — a “double re-rating” candidate (earnings inflection + policy flow).

Q: Should one chase or wait? A: Most of the final 6 have already moved meaningfully. Each has a separate entry condition: Silicon2 wants 43,000–45,000 won support or confirmed breakout, Classys wants ~55,000 won support hold, GlobalTaxFree wants 6,000-won basing with sustained turnover. Wait for the trigger; the chase has worse risk-reward.

Q: What changes in June and July that matters? A: June industry briefings and the July KOSDAQ 30th-anniversary event are when Premium-100 final criteria publish. Whether the market-cap threshold is ₩500bn vs higher, whether the OP threshold is ₩30bn vs higher, and what governance grade is required — those details flip individual probabilities. Re-score the candidate list once the criteria are public.

This article is for research and informational purposes only and does not constitute investment advice. Screening data drawn from a proprietary database; financial cut at 2026-05-07, price-and-flow cut at 2026-05-08. Filter 1 (ROE ≥15%, OP growth positive) applied no liquidity / flow / PER constraints — wide-net design. Filter 2 (ROE ≥25%, ₩1bn turnover) and Filter 3 (margin + growth + flow added) layered for compression. KOSDAQ promotion-relegation reform details from Maeil Business Newspaper (2026-05-10), KRX KOSDAQ Global Segment operational rules, and FSC press releases. Premium-tier final criteria are not yet finalized — list, criteria, and timeline subject to change. APR (KOSPI 278470) and Cosmax (KOSPI 192820) are KOSPI-listed and not direct beneficiaries of the KOSDAQ reform. Individual-name judgments are analytical inferences and may be wrong. Data cut: May 10, 2026 KST.

KOSDAQ Complete Guide for Foreign Investors — 1,820 Listed Companies, About to Be Sliced Into a 3-Tier League. October 2026 Promotion / Relegation Reform Could Finally Open the Pension-Capital Tap

Sun, 10 May 2026 11:00:00 +0900

📚 KOSDAQ Series — Part 1. Continue with: Part 2 — Screening for Quality with ROE: 1,820 → 105 → 35 → 6

While KOSPI breached 7,500 and printed an all-time market-cap high, KOSDAQ has been oscillating around the 1,200 line. YTD 2026 the small-cap board is +30% — not bad in absolute terms, ahead of Turkey, Japan, and Brazil — but less than half of KOSPI’s +75%. The retail-investor complaint is by now familiar: “KOSDAQ doesn’t go up when KOSPI goes up, and goes down when KOSPI goes down.” Underneath the relative-performance frustration, however, the structural change worth tracking has finally surfaced: a promotion-relegation system that splits all ~1,820 KOSDAQ-listed companies into Premium (Tier 1, ≤100 names), Standard (Tier 2), and Watch (Tier 3) segments, with movement between tiers based on earnings and governance. The reform launches as early as October 2026. The point is not to publish another curated list — the 2022 KOSDAQ Global Index already proved the curation worked but the money didn’t follow. This time the design must build the buy-side plumbing too.

TL;DR

What KOSDAQ is. Korea’s growth-equity board, launched in 1996 as a NASDAQ analog. ~1,820 listed companies. Dominated by biotech, semiconductor equipment, gaming, beauty, robotics, battery-materials. The “next-generation Samsung Electronics” tends to start its public-market life here.
Up +30% YTD but overshadowed. That print beats Turkey (+29%), Japan (+18%), Brazil (+16%). But against KOSPI +75%, it reads as relative underperformance — KOSPI’s rally was that large, not because KOSDAQ collapsed.
A 25-year breakout. April 24, 2026 closed at 1,203.84 — the first close above 1,200 since the dot-com peak in March 2000. Driven by breadth (semiconductor-equipment, biotech, robotics, batteries) rather than a single-theme rip.
The reform that matters: October 2026 promotion-relegation. All ~1,820 listed names get split into Premium (≤100), Standard, and Watch. Earnings-based promotion and relegation. The intent: build the institutional plumbing (premium-segment ETFs, NPS benchmark inclusion, ₩6tn People’s Growth Fund) so passive and pension capital have forced exposure to the curated top tier rather than optional.
The legacy problem the reform is trying to fix. KOSDAQ’s index-level top names skew toward names with elevated multiples and unproven earnings — Ecopro BM at PER ~596×, LegoChem Bio at ~286×, Robotis at ~390×, ABL Bio loss-making but at #9 by market cap. A KOSDAQ150 mechanically tilted toward unprofitable names is exactly the kind of benchmark institutions cannot underwrite.
Premium-segment success requires actual buy demand, not just the list. The 2022 KOSDAQ Global Index returned +160% vs. KOSDAQ broad +65% — proving curation works. But it never became a pension benchmark or an ETF magnet. The October reform must avoid that trap.
Why this matters at the name level. Stocks already covered in our prior posts that sit on KOSDAQ — ISU Petasys (substrate stack), OE Solutions (CPO), APR (beauty), Easy Bio (feed-additive platform) — see different forward valuations depending on Premium-tier inclusion. Inclusion = passive flow + NPS attention + liquidity uplift. Exclusion = retail-flow status quo.

1. What KOSDAQ Is — for foreign investors arriving fresh

1.1 Korea’s “second exchange”

Item	KOSPI	KOSDAQ
Character	Large-cap, blue-chip	Growth, innovation
Launched	1956	1996
Listed companies	~950	~1,820
Market cap	~₩6,000tn (8th globally)	~₩673tn
Sector tilt	Semis, autos, financials, energy, shipbuilding	Biotech, semi-equipment, gaming, beauty, robotics
Investor base	Foreign / institutional dominant	Retail dominant (64% of trading volume)
Volatility	Lower	Higher
Index base	1980-01-04 = 100	1996-07-01 = 1,000
Flagship index	KOSPI 200	KOSDAQ 150

KOSPI is the home of Samsung Electronics, SK hynix, Hyundai Motor. KOSDAQ is where the next generation lives. Mapped to the U.S., KOSPI ≈ NYSE and KOSDAQ ≈ NASDAQ.

1.2 The name and the original mission

KOSDAQ stands for Korea Securities Dealers Automated Quotation — a deliberate echo of NASDAQ. The launch mandate was to give SMEs, ventures, and tech companies an equity-funding path that KOSPI’s stricter listing thresholds wouldn’t allow. The Financial Services Commission still describes KOSDAQ as “the core infrastructure of Korea’s innovation and venture ecosystem.”

1.3 KOSDAQ vs. NASDAQ — where they diverge

Item	U.S. NASDAQ	Korea KOSDAQ
Market cap	~$29tn (#1 globally)	~₩673tn (~$500bn)
Flagship names	Apple, Nvidia, Microsoft	Alteogen, Ecopro BM, HLB, Leeno Industrial
Institutional weight	High	Low (retail = 64% volume)
Hosts mega-caps?	Yes (Apple ~$4tn cap)	No (large-caps migrate to KOSPI)
Market perception	“World’s leading tech-stock board”	“Volatile, sometimes speculative”

The single most important divergence: NASDAQ keeps Apple and Nvidia. KOSDAQ loses its winners to KOSPI. 54 companies have transferred from KOSDAQ to KOSPI since launch; the 48 still listed today have a combined market cap of ~₩218tn — more than 30% of KOSDAQ’s entire market cap. The structural weakness is built in: the best-performing companies leave the board. Closing this leak is one of the explicit goals of the October promotion-relegation reform.

2. KOSDAQ’s 30 years — boom, collapse, and a 25-year recovery

2.1 Compressed history

1996.07: Launched at 1,000
1997-1998: Asian financial crisis collapse
2000.03: 2,834 ← all-time high (dot-com peak; not yet broken)
2000.12: 525 ← bubble burst, -80%
2001-2019: Range-bound 400-900 — the "lost two decades"
2020: COVID-low rebound, retail-investor onboarding wave
2022-2024: Rate hikes, capital-gains-tax debate, drift back to 600-800
2025 H2: Government KOSDAQ-revitalization program
2026.01.26: Reclaims 1,000
2026.04.24: Closes at 1,203.84 → first 1,200+ close in 25 years
2026.05: Oscillating around 1,200

2.2 Why the 25-year breakout matters

KOSDAQ has approached 1,200 multiple times and failed each time. The April 2026 break is different because the move was driven by breadth — semiconductor materials/equipment, biotech, robotics, and batteries simultaneously — rather than a single thematic rip.

The relative gap to KOSPI is real and hurts perception. On May 6, KOSPI surged +447 points (+6.5%) and broke 7,000 — KOSDAQ closed -0.3% the same session. “Doesn’t rally with KOSPI, sells off with KOSPI” is the retail complaint that crystallized.

But KOSDAQ +30% YTD is genuinely not bad in absolute terms — it’s ahead of Turkey (+29%), Japan (+18%), Brazil (+16%). The relative softness is a function of KOSPI’s outsized rally, not KOSDAQ deterioration. Why Korea Part 4 covers the $6.7bn foreign ETF inflow that overwhelmingly went to Samsung Electronics and SK hynix — i.e., to KOSPI, not to KOSDAQ. The October reform is one of the explicit channels for redirecting that capital.

3. What’s actually inside KOSDAQ — by sector

3.1 Biotech / pharma — the biggest segment

Most of KOSDAQ’s index-cap top sits in biotech. Korea has begun building real strength in biosimilars, antibody-drug conjugates (ADCs), and cell-and-gene therapy.

Alteogen — subcutaneous-injection drug-delivery platform, licensed to global pharma. Among the largest names in KOSDAQ by market cap.
LegoChem Biosciences — ADC platform with multiple large licensing deals.
ABL Bio — bispecific antibodies. ~#9 by market cap despite a projected ₩48.6bn loss this year.
Kolon TissueGene — gene therapy for osteoarthritis.

The sector is KOSDAQ’s biggest strength and its biggest volatility source. Names move +100% on trial reads and -50% on accounting issues. SamCheonDang Pharmaceutical hit #1 in KOSDAQ market cap at a ₩1.23m share price in March 2026, then collapsed below ₩400k after disclosure-failure designations — a textbook KOSDAQ episode.

3.2 Semiconductor equipment / materials — the AI second derivative

If KOSPI hosts Samsung Electronics and SK hynix, KOSDAQ hosts most of their suppliers.

Jusung Engineering — semiconductor and display deposition equipment.
Wonik IPS — wafer-process equipment.
Leeno Industrial — test sockets and probe pins, leading global market share.
Hanmi Semiconductor — back-end equipment with HBM exposure (a key 2025-2026 AI beneficiary).
ISU Petasys — high-layer-count PCBs for AI servers and switches. Covered in Korea AI PCB Ecosystem: 10 Companies.
OE Solutions — optical transceivers and laser chips, with CPO-related external-light-source products. Covered in Korea Optical / CPO Value Chain — 7 Companies.

This is the segment doing most of the heavy lifting in 2026’s KOSDAQ rally.

3.3 Gaming, beauty, robotics, batteries — the cluster names

Gaming: Pearl Abyss (Black Desert / Crimson Desert global MMORPGs), Wemade, Com2uS, Kakao Games.
Beauty: Classys (medical aesthetics devices, HIFU), PharmaResearch (Rejuran PN skin booster, polynucleotide platform), Silicon2 (global K-beauty distribution platform), Englewood Lab (US-market beauty ODM). See Why Korea Part 2 — Korean Cosmetics for the ecosystem context. Note: APR (KOSPI 278470) and Cosmax (KOSPI 192820) — both well-known Korean beauty names — are KOSPI-listed and outside the scope of this KOSDAQ guide.
Robotics: Rainbow Robotics (bipedal humanoid with Samsung Electronics as strategic investor).
Battery materials: Ecopro BM (cathodes, near top of KOSDAQ market cap, projected PER ~596×).

4. Why KOSDAQ has carried a “casino-board” reputation

4.1 Top-of-cap names with unverified earnings

The Maeil Business Newspaper framing is sharp: KOSDAQ’s highest-market-cap tier is dominated by names with elevated multiples and unproven earnings.

Name	Market cap	2026E net income	Implied PER
Ecopro BM	₩23tn+	Tens of ₩bn	~596×
LegoChem Bio	₩7tn+	~₩40bn	~286×
Robotis	₩5tn	~₩10bn	~390×
ABL Bio	#9 by market cap	-₩48.6bn (loss)	n/m

High multiples on growth names are not, in themselves, a problem — NASDAQ also hosts loss-making names at the cap top. The actual issue is structural: when index methodology elevates unverified-earnings names into KOSDAQ 150, the benchmark itself becomes uninvestable for institutions whose mandates require profitability filters.

4.2 The KOSDAQ 150 design problem

KOSDAQ 150 selects on free-float market cap and trading volume. Under that filter, unprofitable thematic names (battery-materials, biotech, robotics) with inflated caps from expectation alone end up in the index ahead of profitable mid-caps with stable earnings. Pension funds running KOSDAQ 150 as a benchmark are then forced to underwrite that mix. They mostly choose not to.

4.3 The good companies leave for KOSPI

KOSDAQ’s most-successful graduates transfer up to KOSPI to access deeper institutional and foreign liquidity, plus larger passive pools. 54 companies have made that move; the 48 still listed today carry ~₩218tn of market cap — over 30% of KOSDAQ’s total. The board’s structural weakness is that its winners exit.

5. The October Reform — a 3-tier league with promotion and relegation

5.1 What changes

From October 2026 (or as soon as feasible), KOSDAQ’s ~1,820 listed companies get sorted into three tiers:

Premium (Tier 1):
- ≤100 companies
- Selection on financial soundness, growth, governance
- Designed as the destination for pension and passive flows
- New dedicated index + ETF products

Standard (Tier 2):
- Mid- and small-caps below the Premium threshold
- Separate index and ETF products under consideration
- Provides depth, mitigates Premium-only flow concentration

Watch (Tier 3):
- Distressed / problem names
- Accelerated delisting pathway

The promotion-relegation logic is direct: companies move between tiers based on earnings and governance metrics. Same idea as football-league relegation, applied to capital markets.

5.2 Why this matters — “a good list” ≠ “a list institutions must own”

A market-participant quote captures the design lesson:

“We made a list of good companies, but we never built a structure that forces investors to actually own them.”

That refers to the 2022 KOSDAQ Global Index: ~50 selected names, +160% return since launch (vs. KOSDAQ broad +65% same period). The curation worked. The flow didn’t. ETFs tracking the Global Index stayed small. NPS never adopted it as a core benchmark. The October reform’s design intent is to fix that — move beyond curation and build the institutional flow architecture into the system itself.

5.3 Specifically, what flow channels open

1. Premium-index passive flow. A dedicated Premium index becomes the underlying for new ETFs. Passive AUM mechanically buys the Premium 100 — separate from existing KOSDAQ 150 passive demand.

2. NPS benchmark inclusion. If the National Pension Service’s domestic-equity benchmark begins to assign weight to KOSDAQ (per reform discussions, ~5%), then funds and external managers ignoring KOSDAQ underperform their benchmark. “Not buying” becomes a relative-performance penalty rather than a neutral choice.

3. People’s Growth Fund. A ₩150tn (5-year) People’s Growth Fund is being aligned with KOSDAQ. Of the ₩30tn scheduled this year, ₩10tn flows into equity / indirect investment, including special-listing tech companies and pre-listing KOSDAQ pipeline. The ₩600bn People’s Participating subfund launching May 22 carries a minimum 10% (₩60bn) allocation requirement to KOSDAQ tech-special-listing names.

5.4 The “stop the leak to KOSPI” effect

If Premium-tier names can access pension money and passive flows while staying on KOSDAQ, the incentive to transfer up to KOSPI weakens. The structural leak that has cost KOSDAQ its winners for 25 years could finally be plugged.

5.5 Timeline

Now: Korea Capital Market Institute (KCMI) finalizing detail design
June: Market-participant briefings, public comment
July: KOSDAQ 30th-anniversary event — formal disclosure of the reform framework
October (target): Reform goes live

6. The ratio that matters — 50 well-chosen names vs. the broad index

6.1 What the KOSDAQ Global Index already proved

KOSDAQ Global Index (\~50 quality names):
2022.11.21 inception (1,000) → 2026.05.08 (2,602) → +160.2%

Same period:
KOSDAQ broad (\~1,800 names): +65%
KOSDAQ 150 (150 names): +93%
KOSDAQ Global (\~50 names): +160%

The selection-method matters more than KOSDAQ-the-asset-class. Choosing 50 well-screened names returned ~2.5× the broad index. “KOSDAQ doesn’t work” is the wrong framing. “Which KOSDAQ names you own” is the question.

6.2 Premium selection must be earnings-based, not just cap-based

The legacy KOSDAQ 150 was effectively cap-and-volume. That filter inevitably promoted unverified-earnings names — Ecopro BM at PER ~596×, ABL Bio loss-making, Robotis at PER ~390×. The Premium-tier brief explicitly cites financial soundness and growth as the selection criteria. If the implementation actually screens out cap-only names, the resulting benchmark is institutionally underwriteable in a way KOSDAQ 150 has never been.

7. Why this matters for the names we already cover

7.1 KOSDAQ-listed names from our prior posts

ISU Petasys — covered in Korea AI PCB Ecosystem: 10 Companies.
OE Solutions — covered in Korea Optical / CPO Value Chain — 7 Companies.
Easy Bio — covered in Part 1 and Part 2.
Silicon2 / Pamicell — covered in the ROE-25% screen.

For each of these, Premium-tier inclusion is a non-trivial valuation variable.

If included:

Mechanical passive-fund inflow via Premium-index ETFs
NPS-benchmark consideration
Liquidity-tier improvement
Multiple-rerating optionality on the back of cleaner buy-side access

If not included:

Retail-flow regime continues
Institutional access remains gated

7.2 The variables to track from October

The Premium 100 list itself — earnings-based or cap-based? The single most important reveal.
ETF launch pace and AUM — does Premium-index passive AUM reach a meaningful scale?
NPS benchmark adoption — does KOSDAQ actually enter the pension benchmark?
People’s Growth Fund deployment — does the ₩600bn participating subfund meaningfully invest in KOSDAQ tech names?
KOSPI transfer activity — do Premium-tier names stop migrating up to KOSPI?

8. Risks that could neutralize the reform

8.1 “List changes, money doesn’t”

The 2022 KOSDAQ Global Index outcome could repeat. Premium list curated, ETFs launched, but AUM stays small and NPS doesn’t adopt it as a benchmark. Without the institutional pull, capital-flow patterns don’t shift.

8.2 Thematic volatility persists

The reform doesn’t lower KOSDAQ volatility per se. Among the ~1,720 non-Premium names, retail-driven theme rallies and crashes will continue. The “KOSDAQ is risky” perception doesn’t dissolve overnight.

8.3 Diluted Premium criteria

If the Premium tier ends up including loss-making or unverified-earnings names — to satisfy lobbying or political optics — the credibility premise collapses. The criterion has to be earnings, not market cap. Anything else recreates the KOSDAQ 150 problem under a new name.

9. Bottom line

KOSDAQ is a 30-year-old market that still hasn’t recovered its 2,834 dot-com peak. Twenty-five years of “lost market” status. YTD 2026 is +30% with a 1,200 breakout — but KOSPI’s +75% has overshadowed the move and produced more retail frustration than appreciation.

The structural change worth tracking is the October promotion-relegation reform. Splitting ~1,820 listed names into Premium (≤100), Standard, and Watch, with movement based on earnings, is one piece. The piece that matters more is building the institutional plumbing — Premium-index ETFs, NPS-benchmark inclusion, People’s Growth Fund alignment — that forces real flow into the new top tier. If those three pieces work, KOSDAQ-quality names see liquidity and multiple uplift.

The KOSDAQ Global Index already proved the upper bound: 50 well-chosen names returned +160% while the broad index returned +65%. “KOSDAQ doesn’t work” was always the wrong framing. “Which 50 names” was the question. The October reform’s success or failure compresses to two design choices — does the Premium screen prioritize earnings over cap, and does the institutional plumbing actually pull flow.

FAQ

Q: How does KOSDAQ differ from KOSPI for foreign investors? A: KOSPI is large-cap blue-chip (Samsung Electronics, SK hynix, Hyundai Motor, ~950 names); KOSDAQ is growth (biotech, semi-equipment, gaming, robotics, ~1,820 names). U.S. analog: NYSE vs. NASDAQ. KOSDAQ is more volatile and far more retail-dominated.

Q: Who is the largest company on KOSDAQ? A: It rotates frequently. Recently Alteogen, Ecopro BM, HLB, and Leeno Industrial have traded near the top. Because KOSDAQ’s biggest winners migrate to KOSPI (54 names historically — APR and Cosmax are recent examples), KOSDAQ’s “leader” is structurally a newer cohort rather than a stable Apple-equivalent.

Q: Why has KOSDAQ underperformed KOSPI in 2026? A: The $6.7bn YTD foreign ETF flow concentrated in KOSPI mega-caps (Samsung Electronics, SK hynix). KOSDAQ is retail-dominated and pension/foreign access is structurally limited. The October promotion-relegation reform is the explicit attempt to redirect institutional flow into KOSDAQ Premium-tier names.

Q: What does the promotion-relegation system actually do? A: It splits ~1,820 KOSDAQ names into Premium (≤100), Standard, and Watch, with movement between tiers tied to earnings. Combined with new Premium-index ETFs, NPS-benchmark inclusion, and the People’s Growth Fund, the design forces pension and passive capital into the curated top tier. The intent is to break the 25-year leak of KOSDAQ winners to KOSPI.

Q: Which KOSDAQ stocks should I watch around the October reform? A: Focus on profitable mid-caps with sustainable margins — Leeno Industrial, Hanmi Semiconductor, Classys, PharmaResearch, Easy Bio, etc. — that could plausibly meet earnings-based Premium criteria. The list itself is finalized only after October; pre-positioning carries category risk.

Q: What’s the biggest risk that the reform fails? A: The 2022 KOSDAQ Global Index outcome repeating — the Premium list gets curated, ETFs launch but stay small, NPS doesn’t adopt it as a benchmark. Without the buy-side plumbing actually engaging, the new list won’t change flow patterns.

Q: Which KOSDAQ stocks see the largest foreign-investor presence today? A: Names with high foreign-ownership ratios include Alteogen, Leeno Industrial, and HLB. Mostly companies with high overseas-revenue mix, or biotech names with advanced clinical pipelines.

This article is for research and informational purposes only and does not constitute investment advice. Reform-related details rely on Maeil Business Newspaper (2026-05-10, Kim Jung-suk) reporting. KOSDAQ index, market cap, listed-company count, and KOSPI-transfer history sourced from KRX. KOSDAQ Global Index returns from KRX disclosures. KOSDAQ-revitalization policy from FSC (2025-12-19) announcements. KOSDAQ 150 valuation data via FnGuide consensus. Relative-performance and foreign-flow context drawn from Seoul Economic Daily, NewDaily, EBN, and eToday reporting. KB Asset Management’s KOSDAQ Leader fund context from Seoul Economic Daily (2026-05-08). The promotion-relegation reform is not yet finalized — selection criteria, the Premium 100 list, and the launch date may change. Analysis can be wrong. Data cut: May 10, 2026 KST.

Easy Bio Revisited — Korean Feed Stock or Korean Anpario / Phibro? Why the 1Q26 9.4% Margin Print Will Decide the Re-classification

Sat, 09 May 2026 21:00:00 +0900

🔗 Part 1: Easy Bio (353810) Analysis: North America Feed Additive M&A at 6× PER and 27-37% ROE

Part 1 established what the business has become — 78% feed-additive revenue, three North America M&A transactions completed (Devenish, BioMatrix, Nutribins), and a 6× forward PER paired with 27–37% ROE. This follow-up moves to the second-order question: how does the market re-classify the name, and what specifically forces that re-classification. The answer compresses to a single Q1 print. Above 9.4% OPM in 1Q26, the “Korean Anpario / Phibro” label starts to displace the “domestic feed stock” label, and the path to a 10–12× multiple opens. Below it, the feed-stock label sticks, and the global-peer discount becomes structural rather than a re-rating opportunity.

TL;DR

The business has already shifted. 3Q25-cumulative revenue mix: feed additives 78% / feed 22%. Feed-additive revenue grew from ₩94bn (2022) to ₩396bn (2025) — over 4× in three years. The Devenish acquisition was the inflection point.
6× PER vs. 27–37% ROE. Eugene Securities (2026E ROE 36.9%, PER 5.7× at report-date price); Korea IR Council (ROE 26.8%, PER 6.6×). Both versions reach the same conclusion: PER is mispriced relative to ROE.
Global peers trade at 15–18× PER. Phibro (US, animal-health + feed additives) 18.4×; Anpario (UK AIM, small-cap functional additives) 14.6×; Adisseo (Shanghai, amino acids + feed additives) 36.9×; Balchem (US, specialty nutrition + microencapsulation) 32.8×. Easy Bio’s 6× sits at a 50–64% discount to the relevant peer set.
Eugene’s 2026 model. Revenue ₩510.7bn (+7%), OP ₩52.5bn (+17%), OPM 10.3%. Quarterly path: 1Q ₩11.8bn / 9.4% OPM, building to 4Q 11.2%. Target price ₩10,000, BUY.
The US livestock cycle is supportive. Beef prices at multi-decade highs (supply cliff unbroken); broiler inventory falling sharply after the January USDA dietary guideline lifted the protein-intake reference; pork in supply-demand balance. Cattle, hogs, and broilers all under upside pressure on head count — additive demand follows.
The single question. “Is Easy Bio a Korean Sajo / Farmsco, or a Korean Anpario / Phibro?” If the market reads option A, fair PER is 6–8×. If it reads option B, the band opens to 10–15×. The 9.4% 1Q26 OPM print is the first verification gate.

1. What changed since Part 1 — and what’s new in this piece

Part 1 introduced the discovery: a name screened as a “Korean feed stock” had already become a North America feed-additive M&A platform with 78% additive mix and a high-ROE / low-PER pairing. This piece adds three things on top:

A peer-comparable multiple table. Phibro 18.4×, Anpario 14.6×, Adisseo 36.9×, Balchem 32.8×. The question becomes: how much of Easy Bio’s 50–64% discount is justified, and how much is the legacy-label tax?
A decomposition of the “feed stock” label discount. Justified components (size, liquidity, coverage breadth, M&A integration not fully tested) vs. excessive components (business-mix change not yet reflected in classification).
A specific verification gate. 1Q26 OPM 9.4% as the line above which “feed-additive platform” reclassification stays alive, below which the discount compresses back to feed-stock convention.

The summary, in one sentence: Part 1 was the discovery; Part 2 is the framework for what proves or invalidates the re-classification.

2. Business mix — additive revenue 4× in three years

2.1 Annual top-line trajectory

(Eugene Securities estimates, KRW bn)

Item	2022	2023	2024	2025	2026E
Feed additives	94.4	109.3	305.7	395.6	427.8
Piglet feed	79.1	81.9	103.0	109.2	109.8
Total	155.6	165.4	384.3	476.9	510.7
Additive mix	~61%	~66%	~80%	~83%	~84%

Cross-checks:

2025 additive mix = 395.6 / 476.9 = 82.9% ≈ 83% ✓
2026E additive mix = 427.8 / 510.7 = 83.8% ≈ 84% ✓

The 2024 step-change (₩109bn → ₩306bn) reflects Devenish consolidation. All forward growth is in additives; piglet feed has plateaued near ₩100–110bn.

2.2 Margin structure post-Devenish

Quarter	OP (₩bn)	OPM	Note
1Q25	9.1	7.8%	Early post-Devenish
2Q25	11.0	9.7%	Incentive bonus phase ends
3Q25	11.2	9.6%	Margin holds
4Q25	13.6	10.5%	~11% ex-acquisition diligence costs
1Q26E	11.8	9.4%	Lower-half loaded (‘상저하고’)
4Q26E	14.8	11.2%	Improvement through year-end
2026E (FY)	52.5	10.3%	—

Eugene flags: “post-Devenish, even with incentive-bonus normalization, margin continues to improve” — i.e., structural margin improvement, not a one-quarter integration spike.

A revenue-₩500bn company sustaining 10%+ OPM is not a “feed stock” in conventional Korean equity-screen taxonomy.

2.3 ASP per kilogram is also rising

Eugene’s chart on p. 3 shows feed-additive ASP/kg rising consistently — i.e., it’s not just volume growth, it’s mix-up. The shift away from commodity blended feeds and into functional additives (enzymes, emulsifiers, probiotics, coated products) is structurally raising the unit price.

3. The three North America M&A — what they actually mean

3.1 Devenish — the platform anchor

Devenish North America:
- 4 US plants + 1 Mexico plant
- Pork / poultry / ruminant species coverage
- Blended feed + functional additives manufacturing
- Located in core hog states (Iowa, Minnesota)

Eugene’s p. 4 maps Devenish NA, Pathway USA, BioMatrix, and Nutribins onto the US livestock geography — top hog states (IA / MN / NC / IL / IN), top broiler states (GA / AL / AR), top cattle states (TX / NE / KS) — with the Easy Bio entities adjacent.

3.2 BioMatrix + Nutribins — mix-upgrade additions

Closed January 2026:

BioMatrix: coating-technology specialist. Eugene expects “additive coating technology” to lift Devenish’s earnings trajectory. Targeted gut-delivery of active ingredients drives product differentiation and pricing power.
Nutribins: high-value additive raw materials + incremental sales channel. Eugene estimates ₩2.0–2.5bn annual earnings contribution. Korean industry coverage (Hando-news) frames the strategic logic as Devenish’s R&D base + Nutribins’ raw-material solutions = expanded North America functional-nutrition platform.

3.3 Eugene’s report title: “This Company Just Manages Well”

Eugene’s report title (2026-04-02, analyst Heo Jun-seo) says exactly that: “이 회사는 그냥 경영을 잘함” — this company just manages well. The point of the title is to frame M&A → operating-result conversion as the variable, not the M&A itself. Eugene’s quote on the 4Q25 print: “₩13.6bn OP despite acquisition due-diligence costs; ex-DD that’s ₩14bn+. US feed-additive market influence continues to expand.”

4. The US livestock cycle is constructive

Eugene’s p. 5–6 covers this. In one sentence: cattle, hogs, and broilers all face head-count pressure higher.

4.1 Beef — supply cliff, prices at multi-decade highs

US beef prices sit at the high end of a 20-year range. The herd-rebuild cycle has not yet absorbed the supply cliff — head counts must rise, and feed/additive demand follows.

4.2 Broilers — inventory drop after the January USDA protein-intake update

The most interesting datapoint Eugene flags: after USDA’s January 2026 dietary-guideline update raised the protein-intake reference, broiler inventory dropped sharply. Broilers respond fastest (short cycle), so falling inventory in the species with the fastest supply response means demand is outrunning supply.

4.3 Pork — supply-demand balance

Pork inventories are in equilibrium with demand — neither overhang nor shortage, holding mid-cycle.

4.4 What this means for feed companies

Eugene’s read:

“Piglet feed and commodity additives can pass through cost inflation without margin damage given the strong livestock backdrop. Within finished additives, the mix has shifted from microbials and extracts toward digestion-enhancing enzyme additives — i.e., cost-saving products for farmers under purchasing-power pressure. The bipolar mix gives the company resilience to mid-cycle swings.”

The structural insight: higher grain costs don’t necessarily compress feed-additive margins — when farmers face cost pressure, they raise demand for additives that boost feed efficiency (like digestion enzymes).

5. The peer comparison — why “feed stock” multiples understate the case

5.1 The right peer set isn’t Korean feed stocks

Comparing Easy Bio to Korean feed names (Sajo, Farmsco, Woosung, Korea Industrial Corp.) makes 6–8× PER look natural. But if 78% of revenue is functional feed additives and the company is building a North America M&A platform, the peer set has to change.

Company	Listing	Business	PER	Comparability
Phibro	NASDAQ	Animal health + mineral nutrition + feed additives	18.4×	Most direct
Anpario	UK AIM	Small-cap functional feed additives	14.6×	Closest size match
Adisseo	Shanghai	Amino acids + feed additives (large cap)	36.9×	Upper bound reference
Balchem	NASDAQ	Specialty nutrition / microencapsulation	32.8×	Coating-tech upper bound
Sajo	KOSPI	Feed + integrated livestock	—	Korean lower-bound
Farmsco	KOSPI	Blended feed + livestock	—	Korean lower-bound
Easy Bio	KOSDAQ	78% additives + 22% piglet feed	6.0×	—

5.2 Phibro — the most directly comparable case

Phibro is a US-listed animal-health / mineral-nutrition / feed-additive specialist. Acquired Zoetis’s medicated feed additive business in 2024 for US$350m (~₩470bn). The acquisition logic — bolt-on M&A onto a feed-additive platform — is closest to Easy Bio’s Devenish-BioMatrix-Nutribins sequence.

Phibro market cap ~₩23tn (US$1.77bn), PER 18.4×. Easy Bio market cap ~₩250bn, PER 6.0×. Same business architecture, ~3× multiple gap.

Of course Phibro has US listing, global customers, scale, liquidity, and disclosure depth that Easy Bio does not. Easy Bio cannot inherit Phibro’s full multiple. A discount is warranted. But “same business, 3× multiple gap” raises the question of whether the discount is well-calibrated — or whether it’s still anchored to a label.

5.3 Anpario — the closest size-and-strategy match

Anpario is a UK AIM small-cap functional feed-additive business. Acquired Bio-Vet (US) in 2024 to expand its North America footprint. The M&A path mirrors Easy Bio’s.

Anpario PER 14.6×. Easy Bio PER 6.0×. If a small-cap functional-additive listed name realistically clears 14–15×, Easy Bio’s 6× is at least partially a “feed-stock label tax.”

5.4 Justified discount vs. excess discount

Justified components:
- Size gap (Easy Bio ₩250bn vs. Phibro ₩23tn)
- Korean small-cap liquidity discount
- M&A integration not fully verified at the consolidated P&L level
- KOSDAQ listing limits global investor accessibility
- Coverage is narrow (Eugene-led, \~3 reports)

Excess components:
- 78% additive mix not yet reflected in classification
- 27–37% ROE at 6× PER is a rare combination even in the Korean market broadly
- 2025 OP +39%, 2026E OP +17% — earnings are following
- 50–64% discount to the relevant global peer set

5.5 The single question

“Is Easy Bio a Korean Sajo / Farmsco, or a Korean Anpario / Phibro?”

Read A → fair PER 6–8×. Read B → fair PER 10–15×. The classification flip is the re-rating event.

6. Valuation scenarios

6.1 Reference numbers

Item	Eugene Securities	Korea IR Council
2026E revenue	₩510.7bn	₩483.6bn
2026E OP	₩52.5bn	₩46.4bn
2026E OPM	10.3%	9.6%
2026E EPS	₩1,252	₩904
2026E ROE	36.9%	26.8%

Cross-checks:

Eugene OPM = 52.5 / 510.7 = 10.28% ≈ 10.3% ✓
Korea IR OPM = 46.4 / 483.6 = 9.59% ≈ 9.6% ✓

6.2 Scenario fair-value bands

(Reference price ₩7,660, May 8 close)

Scenario	EPS assumed	Multiple	Fair value	Vs. current
Bear (Korean feed-stock cap)	₩904	8×	₩7,232	-5.6%
Base (small-cap additive)	₩904	10×	₩9,040	+18.0%
Bull (Anpario discount)	₩1,252	10×	₩12,520	+63.4%
Re-rating (platform)	₩1,252	12×	₩15,024	+96.1%
Eugene TP	₩1,252	8×	₩10,000	+30.5%

Cross-checks:

Eugene TP implied multiple = 10,000 / 1,252 = 7.99× ≈ 8.0× ✓
Bear = 904 × 8 = 7,232 ✓
Re-rating = 1,252 × 12 = 15,024 ✓

Eugene’s ₩10,000 TP is EPS ₩1,252 × ~8× — i.e., still a “feed-stock upper-bound multiple,” not a “feed-additive platform multiple.” A successful re-classification opens upside above the published TP.

7. The single most important verification — 1Q26 OPM

7.1 Eugene’s 1Q26 forecast

Item	1Q26E
Revenue	₩125.7bn
OP	₩11.8bn
OPM	9.4%

Eugene models 2026 as “lower-half loaded” — 1Q OPM 9.4%, building to 4Q OPM 11.2%.

7.2 Why 9.4% is the line

≥ 9.4% → 2026 full-year 10%+ OPM path stays alive
 → "Korean Anpario / Phibro" classification stays in play
 → 8–10× multiple supported

< 9.0% → Mix-shift slower than modeled OR cost pressure rising
 → Reads as "M&A done but margin underdelivering"
 → Multiple compresses back to 6–7×

The 1Q26 print is the first and most important verification gate for the entire thesis.

8. How the “feed stock” label gets dissolved (or doesn’t)

8.1 Why labels matter for multiples

Korean equity classification is not cosmetic — it directly drives the multiple. “Feed” classification carries automatic discounts: livestock-cycle sensitivity, grain-price exposure, small-cap discount.

Easy Bio sits at 78% additive mix but is still classified as “feed.” That’s a legacy frame from before Devenish, and it is what produces the 6× multiple.

8.2 Two paths the label dissolves

Path A — through earnings. Each quarter that prints OPM 10%+ erodes the “feed-stock margin” framing. Sell-side coverage expansion accelerates the process.
Path B — through reclassification. Sector reclassification from “feed” to “consumer / global livestock solutions” lifts the baseline multiple. This is slower but more durable.

Both take time. The fact that foreign and institutional flows have started to coincide is consistent with a “front-running before earnings confirmation” pattern.

8.3 Why the label might not dissolve

If Devenish stays anchored to commodity blended feeds and OPM doesn’t sustain 10%+
If M&A integration drags and Devenish / BioMatrix / Nutribins look like growth-by-acquisition without margin pickup
If the US livestock cycle rolls over and additive demand softens with it
If sell-side coverage stays Eugene-led at 3–4 reports and broader market interest never builds

If any of these hold, the 6× PER becomes “fair value” rather than “discount” — and the discount becomes structural rather than a re-rating opportunity.

9. Signals to track

9.1 The single most important — OPM

1Q26 OPM ≥ 9.4% → 2026 10%+ path stays alive
Quarterly OPM trajectory matches Eugene’s “lower-half loaded” model
Feed-additive ASP/kg keeps rising — mix-shift continues

9.2 M&A earnings contribution

BioMatrix turn-to-profit
Nutribins ₩2.0–2.5bn earnings contribution materializing
North America revenue mix shift

9.3 US livestock cycle

Beef supply-cliff resolution timing
Broiler inventory rebuild pace
USDA policy posture (the protein-intake reference change was the key 2026 catalyst)
Grain-price trajectory (urea-driven harvest impact in particular)

9.4 Re-classification signals

New sell-side coverage initiations
Foreign-ownership ratio (currently ~8%) drift
Domestic institutional ownership build

9.5 Invalidation conditions

OPM drops to 8.5% or lower
2026E OP revised down to ₩45bn or lower
BioMatrix / Nutribins integration shows top-line only, no margin pickup
Repeat M&A funded with debt, no integration return

10. The bottom line

Easy Bio screened as a feed stock makes 6× PER look natural. But 78% of revenue is feed additives, the company runs four US plants and one in Mexico, and it has added a coating-technology specialist and a high-value-additive supplier. Phibro trades at 18×, Anpario at 15×, Adisseo at 37×. Easy Bio’s 6× sits at a 50–64% discount.

Some of the discount is justified — size, liquidity, coverage, integration not fully verified. But a portion is the legacy “feed-stock” label being applied to a business that has already changed. Eugene Securities models 2026 revenue ₩510.7bn, OP ₩52.5bn, OPM 10.3% with a ₩10,000 TP. The 1Q26 OPM 9.4% print is the first verification gate.

The single question is: “Korean Sajo / Farmsco, or Korean Anpario / Phibro?” Read A: 6–8× PER. Read B: 10–15× PER. If 1Q26 prints OPM in the 9.5–10% zone and it persists, the case shifts from “feed-stock upper-bound 8–9×” to “high-ROE functional-additive platform 10–12×.” The US livestock cycle — beef supply cliff, broiler inventory drop, USDA protein guideline — is supportive of that path.

Labels move when earnings move them. The 1Q26 print is where that starts.

FAQ

Q: Is Easy Bio a feed stock or a feed-additive company? A: Mix says it’s already a feed-additive company — 78% of revenue (3Q25 cumulative) is feed additives. The market still classifies it as a feed stock, which is the entire source of the multiple discrepancy.

Q: Is 6× PER actually cheap? A: A name with 27–37% ROE trading at 6× PER is generally cheap, full stop. Some discount is justified (size, KOSDAQ liquidity, integration not fully proven). The question is whether justified discount = 50–64% off the relevant peer set, or less.

Q: Are Phibro / Anpario the right comparables? A: Anpario is the closest match by business model (small-cap functional additives + North America M&A). Phibro is bigger and more globally established. The 15–18× peer-average band, set against Easy Bio’s 6×, frames the available re-rating space.

Q: Why is the 1Q26 OPM print the verification gate? A: Above 9.4% → 2026 full-year 10%+ OPM path is intact, and the “feed-additive platform” reclassification stays alive. Below 9.0% → reads as “M&A done but margin underdelivering,” and the multiple compresses back to 6–7×.

Q: Is the US livestock cycle really constructive? A: Near-term, yes. Beef supply cliff, broiler inventory drop after the January USDA protein-intake change, pork in balance. The downside scenario (rising grain costs + farmer purchasing-power compression) does have some bite, but Easy Bio’s additive-heavy mix offers more defense than commodity feed.

Q: Should one buy at the current price? A: Pre-1Q print, caution is reasonable. ≥9.4% in 1Q is the first signal of the “feed-stock multiple → feed-additive platform multiple” path activating. Verification before entry has a better risk-reward than the chase.

Q: What invalidates the thesis? A: OPM falling to 8.5% or below, 2026 OP revising to ₩45bn or lower, BioMatrix / Nutribins integration delivering only top-line without margin lift, debt-funded repeat M&A without integration returns.

This article is for research and informational purposes only and does not constitute investment advice. Eugene Securities’s 2026-04-02 report (analyst Heo Jun-seo) is the primary source; Korea IR Council, Growth Research, and NH Investment & Securities reports were used as cross-references; global peer multiples (Phibro, Anpario, Adisseo, Balchem) sourced from Yahoo Finance and SEC filings — point-in-time and subject to change. Easy Bio’s North America entity-level financials are not publicly broken out. Coverage is narrow and may carry a positive-tilt bias. Analysis can be wrong. Data cut: 2026-05-07–08 KST.

Korea Optical & CPO Value Chain — Only OE Solutions (138080.KQ) Is Truly Close to CPO; Six of Seven Names Are Up +300–900% YTD With Earnings That Haven't Followed

Sat, 09 May 2026 20:00:00 +0900

🔗 Related: AI PCB & Substrate Hub · Korea AI PCB Ecosystem — 10 Companies · AI PCB & Substrate Thesis — System BOM as the Common Bottleneck · Haesung DS — Lead Frame to AI Heat-Spreader Second-Source

The substrate-thesis post made a system-BOM argument: AI demand isn’t bought one chip at a time, it’s bought one rack at a time, and substrate demand sits across the entire BOM. The same logic now extends down to optical interconnect — and the Korean listed exposures are far less mature. Seven names sit on the optical / CPO axis. Only one (OE Solutions, 138080.KQ) is genuinely close to the new CPO architecture via its ELSFP external laser source. The other six are downstream beneficiaries or themes. And six of seven are up +300% to +905% YTD against operating losses or unverified customer wins. This is a “valid technical thesis at the wrong price” market — exactly the kind of setup where mapping the value chain by distance to the actual bottleneck is more useful than buying the most-up names.

TL;DR

Among Korean listed names, only OE Solutions (138080.KQ) is truly close to CPO. It has disclosed an ELSFP external laser source product (CPO-compatible, OIF-standard 8-channel, 23dBm/200mW per channel, TEC-cooled, customer samples planned for 3Q26) and developed a domestic-first 100G EML laser chip. The other six are not on the CPO core path. OE Solutions is also not yet named on Nvidia’s or Broadcom’s public CPO partner list.
Optocore has actual AI data-center optical transceiver contracts totalling ~₩16.7bn — but the customer is undisclosed and trading is suspended on a 1Q26 going-concern audit. Not investable.
Daehan Optical Communications is +905% YTD on a “more optical fiber for AI” narrative — not a CPO play at all. It’s a vertically integrated preform-to-fiber company, not an optical engine or laser supplier. The Korea Exchange has flagged it for investment-warning escalation.
Six of seven names are up +300%+ YTD against still-loss-making P&Ls. Daehan +905%, BWE +778%, WooriRo +616%, OE Solutions +307%. The price moved long before the earnings followed. Buying here is a bet on price catching up to its own forward expectations, not on the technology being right.
The clean allocator read is OE Solutions watchlist with a wait, the other six on hold. OE Solutions trades at >100× 2026E OP at the current price — the entry is at the 47,000–50,000 won pullback or after 3Q ELSFP customer-sample confirmation, not on chase.

1. Why optical is the next AI data-center bottleneck

1.1 Same logic as substrate — at the network layer

The substrate thesis was a “common-denominator” argument: every additional chip in an AI rack — GPU, CPU, DPU, NIC, switch ASIC, memory module — adds substrate demand. Optical interconnect is the same logic at the network layer. Tens of thousands of GPUs in a single training cluster require network bandwidth that electrical signaling cannot deliver at acceptable power. So the link goes optical.

AI data-center optical demand path:

Tens-of-thousands GPU cluster
 ↓
Switch ASICs (network connectivity)
 ↓
800G → 1.6T optical transceivers (electrical → optical → electrical)
 ↓
Optical fiber and cable plant (the path the light travels)
 ↓
Components: lasers, photodetectors, optical amplifiers, low-loss fiber

Broadcom has indicated that lead times on optical-transceiver PCBs have stretched from 6 weeks to 6 months — an early signal that optical components are becoming the constrained layer.

1.2 What CPO actually is

The legacy architecture used pluggable optical modules plugged into the front of the switch chassis. Easy to swap, but power-hungry, and the electrical signal travels a long path from the switch ASIC out to the front panel.

Co-Packaged Optics (CPO) is a different architecture: the optical engine sits right next to the switch ASIC on the same package substrate. Electrical-signal travel distance collapses. Power per bit drops sharply.

Nvidia has stated its CPO-based switch is 5× more power-efficient and offers 10× better network reliability than pluggable equivalents.
Broadcom has shown a 51.2 Tbps CPO Ethernet switch claiming >70% reduction in optical-link power consumption.

1.3 Why “external laser source” matters inside CPO

The hard problem inside CPO: lasers are temperature-sensitive, switch ASICs are hot. Putting the laser inside the package, next to a hot ASIC, shortens laser life and degrades performance.

Solution: separate the laser from the package. Pull the laser out to the front panel, send only the light into the package via fiber, and keep the laser body thermally isolated.

The standard form factor for that external laser is ELSFP — External Laser Small Form-factor Pluggable, defined by OIF (Optical Internetworking Forum). Once CPO scales, ELSFP becomes a core component category.

Where ELSFP sits inside CPO:

Switch ASIC (hot)
 ↓ (light in)
Optical engine (next to ASIC, light ↔ electrical)
 ↑ (light out)
ELSFP external laser source (front panel, thermally isolated)
 ↑
Laser (high-power, stable)

OE Solutions’s ELSFP is exactly this part. It’s the only Korean listed company with this specific product disclosed.

2. The seven Korean names — separating “true CPO exposure” from “AI optical thematic”

#	Company (ticker)	Value-chain position	AI optical relevance	YTD price	Read
1	OE Solutions (138080.KQ)	CPO ELSFP / optical transceiver / laser chip	Most direct	+307%	Core watchlist
2	Optocore	AI data-center transceivers	Contract evidence; suspended	+106%	Not investable
3	Daehan Optical Communications	Fiber and cable (upstream materials)	Downstream beneficiary, not CPO	+905%	Overheated; KRX warning escalation
4	BWE	800G / 1.6T transceiver line-up	Product disclosed; customer unconfirmed	+778%	High-vol thematic
5	WooriRo	Photodetectors (transceiver core component)	Tech-development stage	+616%	Component option
6	Lycom	Optical amplifiers / DC connectivity	Downstream beneficiary	+98%	Event-pending
7	Coset	Optical components (TOSA/ROSA)	Small-cap option	-5%	Liquidity-inadequate

2.1 What this table shows

First, true CPO exposure vs. AI optical thematic are different objects. Only OE Solutions has the ELSFP external-laser product. The rest are transceivers (Optocore, BWE), fiber (Daehan Optical), photodetectors (WooriRo), amplifiers (Lycom), or generic components (Coset). All sit somewhere in the broader AI optical value chain, but “core CPO supplier” and “thematic optical name” do not deserve the same multiple.

Second, six of seven are up several hundred percent YTD against operating losses or unverified customer wins. Daehan +905%, BWE +778%, WooriRo +616%, OE Solutions +307%. Price moved before earnings. Buying here is not “is the technology right?” — it’s “did price already overshoot what the earnings can deliver?”

3. OE Solutions — the only name truly close to CPO

3.1 Business structure

OE Solutions makes optical transceivers and laser chips. Founded in 2003 by Bell Labs and Samsung Electronics alumni with optical-volume-manufacturing backgrounds. International footprint: New Jersey and California (US), the Netherlands, Japan.

Core capability: vertical integration from laser chip → optical sub-assembly → finished transceiver. In an optical transceiver, the laser is the “engine” — light-output stability, thermal management, and lifetime drive the product. OE Solutions develops the laser chip in-house.

3.2 Why ELSFP is the key product

Disclosed at OFC 2026 (March):

OE Solutions's CPO-compatible ELSFP:

- 23 dBm / 200 mW optical output per channel
- TEC (thermo-electric cooler) integrated → wavelength stability + laser lifetime
- 8-channel configuration
- Customer samples planned from 3Q26

This product directly addresses the CPO thermal isolation problem — pulling the laser away from a hot switch ASIC and locating it on the front panel. OIF defines the standard, and OE Solutions is the only Korean listed name with the disclosed product.

OE Solutions also disclosed at AI EXPO 2026 a domestic-first 100G-class EML laser chip, the foundational light source for 800G/1.6T transceivers.

3.3 The earnings haven’t caught the technology

This is the gap that defines the trade.

Metric	2024	2025	2026E
Revenue (KRW bn)	32.0	57.4	81.6–83.5
Operating profit (KRW bn)	-30.4	-16.0	6.1–6.5
Operating margin	-95%	-28%	7–8%
Datacom revenue mix	—	2%	still low

2025 revenue recovered +79% YoY but stayed loss-making. 2026E flips to profit (₩6.1–6.5bn OP), but the market cap is ~₩660bn. Quick check:

Enterprise value ≈ market cap + net debt = 660 + 20 = ~₩680bn
On 2026E OP of ₩6.5bn → EV/EBIT ≈ 105×

At the current price you’re paying ~105× 2026E OP. That is not a “2026 turn-to-profit” valuation. That is an “AI optical revenue inflection in 2027–2028” valuation.

3.4 Revenue mix is not yet AI-centric

2025 revenue mix (sell-side estimates):

Segment	Share	Read
Wireless	48%	Legacy core; recovering after the post-5G slowdown
FTTH / MSO (wired access)	23%	Tied to Japanese / US wired-access spend
Long-haul (Telecom)	21%	100G/400G long-haul transceivers
Datacom	2%	The AI story is not yet in revenue
Laser chips	6%	Tech option, scale still constrained

Calling this an “AI data-center CPO company” overshoots the current P&L. The accurate framing is “telecom-equipment recovery turnaround with a CPO call option attached.”

3.5 So why is it #1?

What only OE Solutions has, vs. the other six:

1. Disclosed CPO ELSFP product — only one
2. In-house 100G EML laser chip — only one
3. Vertical integration: laser chip → sub-assembly → module — deepest in cohort
4. Track record with global telecom-equipment customers (Cisco, Nokia, Ciena, etc.)
5. International operations footprint (US / NL / JP)

The cautionary note: Nvidia’s disclosed CPO partner list (TSMC, Coherent, Corning, Foxconn, Lumentum, Senko, Sumitomo, etc.) does not include OE Solutions. The accurate state is “tech is there, ecosystem inclusion not yet confirmed.”

3.6 Track these variables

3Q26: Did ELSFP customer samples ship on schedule?
4Q26 → 2027: Is qualification progressing? Are customer names being mentioned?
Datacom mix: Does it move materially above 2%?
Gross margin: Recovery from 2025’s 10.5% toward 20%+?
Operating profit: Did the FY26 turn-to-profit actually print?

4. The other six names

4.1 Daehan Optical Communications — +905% YTD, KRX investment-warning escalation

Daehan is not a CPO company. It’s a vertically integrated preform → fiber → cable manufacturer — upstream materials, not optical engines. AI data centers do consume more high-density fiber, but that’s a downstream beneficiary thesis, not CPO core.

The price action is the issue:

Daehan Optical Communications:
YTD: +905%
3-month: +610%
1-week: +47%
KRX: 2026-05-08 designated as investment-caution stock; warning escalation pending

Foreign flow has been strong, but the regulatory layer is already flagging the move. A 10×-YTD stock buy here is not a fiber-demand bet — it’s a “can the price extend further from a 10× base” bet.

4.2 BWE — +778%, -36% from peak

BWE disclosed an 800G / 1.6T transceiver lineup at AI EXPO. Disclosed product ≠ qualified customer. No core customer name confirmed. Up +778% YTD, down -36% from the peak (8,100 → 5,200 won). Currently in a digestion zone.

4.3 WooriRo — +616%, retail-led spike

Disclosed 200 Gbps photodetector technology — a potential core component for 800G / 1.6T transceivers. Still development-stage; global customer qualification unverified. Cumulative net buying skews retail. This is a thematic-momentum trade, not institutional accumulation.

4.4 Lycom — +98%, dead volume

Optical amplifiers for intra- and inter-data-center connectivity. Reports of overseas order growth. Closer to AI optical periphery than CPO core. Up +98% YTD (least overheated of the seven), but volume sits at 34% of the 3-month average — without a new catalyst, it sideways.

4.5 Optocore — trading suspended, not investable

AI data-center transceiver contracts of ~₩16.7bn aggregate are real. But trading was suspended in March 2026 on a going-concern audit qualification, with possible delisting. No action possible as a public-equity name today.

4.6 Coset — KONEX-listed, liquidity-inadequate

Maker of 400G+ TOSA/ROSA optical components. KONEX-listed (Korea’s smaller equity board); turnover is too thin for normal allocation. Watchlist only.

5. The overheating, in numbers

5.1 YTD performance

Stock	YTD	3-month	1-week	Status
Daehan Optical	+905%	+610%	+47%	KRX warning pending
BWE	+778%	+321%	+2%	-36% off peak, decelerating
WooriRo	+616%	+513%	+7%	Retail-led spike
OE Solutions	+307%	+232%	+38%	Institutional re-entry; still expensive
Optocore	+106%	+14%	—	Suspended
Lycom	+98%	+114%	+2%	No volume
Coset	-5%	+11%	-13%	Liquidity-inadequate

5.2 The single-line read

Four of seven are up >300% YTD with effectively no earnings support. OE Solutions still posted a ₩16bn 2025 operating loss. Daehan is profitable but not profitable enough to justify a 10× YTD move. The price has moved well ahead of the fundamentals.

In this regime, the deciding question is not “is the technology right?” — it’s “did the price already pull forward more than the earnings can ever deliver?”

6. OE Solutions valuation — what you’re actually buying at the current price

6.1 What the current price requires

Assume market cap ~₩660bn, net debt ~₩20bn, EV ~₩680bn.

At an EV/EBIT exit multiple of 30×, the OP required to justify each price level:

Price	Required OP (at 30× EV/EBIT)	Vs. 2026E OP
53,300 (current)	~₩22.7bn	3.5× consensus
60,000 (street TP)	~₩25.4bn	3.9× consensus
70,000	~₩29.5bn	4.5× consensus
100,000	~₩41.9bn	6.4× consensus

Even the current price requires OP ~3.5× the 2026E consensus to reconcile to a 30× multiple. That isn’t a 2026 number. That’s a 2027–2028 AI-optical-revenue inflection.

6.2 Scenario fair-value bands

Scenario	Key assumption	Operating profit	Fair-value band (KRW)
Bear	Telecom recovery delayed, ELSFP samples slip	₩0–5bn	25,000–35,000
Base	FY26 turn-to-profit, ELSFP at sample stage only	₩6.1–6.5bn	30,000–45,000
Bull 1	2027–2028 datacom revenue ramp	₩20–25bn	47,000–59,000
Bull 2	ELSFP customer adoption, GM 15%+	₩30–40bn	71,000–111,000
Hyper-bull	Direct inclusion in global AI CPO supply chain	₩40bn+	110,000+

The 53,300 close sits between Bull 1 and Bull 2 — already pricing in meaningful CPO option value on top of the telecom-recovery base. If 3Q ELSFP customer engagement materializes, the price extends. If not, the level is exposed.

7. Position framework — how to handle the seven

#	Name	Read	Rationale
1	OE Solutions	Core watchlist, wait	Highest CPO purity; price already rich. Wait for 47,000–50,000 pullback or 3Q ELSFP confirmation
2	Lycom	Event-pending	Less overheated, but no volume — needs an order or customer-disclosure catalyst
3	Daehan Optical	No chase	+905% with KRX warning pending. Holders trim; new entries inappropriate
4	BWE	Wait for re-break	-36% off peak; pause until customer confirmation
5	WooriRo	No new entry	Retail-led; technology unverified
6	Optocore	Not investable	Trading suspended, delisting risk
7	Coset	Watch only	KONEX, liquidity-inadequate

7.1 OE Solutions entry conditions

Price: First interest at 47,000–50,000 zone. Second interest at 43,000–45,000 (deeper retest).

Earnings confirmation:

2Q or 3Q operating-profit print (turn-to-profit confirmation)
3Q ELSFP customer-sample shipment disclosure
Datacom revenue mix moving up

Flow confirmation:

Foreign + institutional concurrent net buying ≥ 3 sessions
Stable settlement above the 52-week high (57,900)

7.2 Invalidation conditions

FY26 fails to turn to profit
3Q ELSFP sample timeline slips
No customer-qualification mention through 4Q
Datacom mix stays below 10%
Gross margin fails to recover above 20%

8. Three things that need to be said directly

8.1 Most of the seven are thematic stocks

Honestly: among the seven, almost none have earnings-validated cases. OE Solutions was operating-loss in 2025, and the rest are weaker. Stocks up several hundred percent without operating profit are priced on expectation, not delivery. When expectation is not converted into earnings, the price gives back.

8.2 No Korean small-cap is on Nvidia’s CPO partner list

Nvidia’s named CPO partners: TSMC, Coherent, Corning, Foxconn, Lumentum, Senko, Sumitomo. No Korean small-caps. Asserting “Korean companies are inside the CPO supply chain” is overreach. OE Solutions is the closest but is still a candidate, not a confirmed inclusion.

8.3 Optical investing has long lead times

Optical-transceiver qualification cycles run like semiconductors: sample → qualification → design adoption → volume order → revenue recognition can take 1–2 years. Even if 3Q26 samples ship on time, volume revenue may be 2027–2028. Whether the share price waits patiently through that window is not knowable in advance.

9. Connecting back to the substrate series

This piece sits in the same frame as the substrate series. The system-BOM thesis made the structural argument that AI demand is bought as systems, not chips. That system contains substrate, optical, thermal, and power layers — all of them stretched.

AI system common bottlenecks:

Substrate (FC-BGA, MLB, CCL) — covered in the 5-name and 10-name pieces
Optical (800G/1.6T modules, CPO ELSFP, fiber) — this piece
Thermal (heat spreader, heat slug) — covered in the Haesung DS piece
Power (transformers, power semis) — future post candidate
Cooling (immersion, heat sinks) — future post candidate

The 10-companies framework argued that the substrate-shortage thesis funnels back into upstream materials. The same distinction applies here — fiber and cable (Daehan Optical) is a downstream beneficiary, while laser / external-laser-source (OE Solutions) sits closer to the actual CPO bottleneck.

The crucial difference: the substrate cluster has earnings catching up with the price. The optical cluster does not. Substrate is “pick the validated names trading at acceptable prices.” Optical is “separate signal from noise inside an overheated, pre-earnings rally.”

Haesung DS provides the same contrast on the thermal axis: there, the AI heat-spreader optionality sits on top of a real automotive-LF and DDR-substrate base. Here, five of seven optical names lack a comparable base — the optionality is essentially the entire thesis.

10. The bottom line

Optical interconnect being the next AI data-center bottleneck is structurally correct. Tens of thousands of GPUs need 800G / 1.6T optics, and CPO is the credible architectural answer. Korea has seven listed exposures.

But only one of the seven is genuinely close to CPO core. OE Solutions has the ELSFP external-laser source and the in-house 100G EML chip. The other six are downstream beneficiaries or themes. And six of seven are up +300% to +905% YTD — Daehan Optical with a KRX investment-warning escalation pending on top.

OE Solutions itself trades at ~105× 2026E OP. Datacom mix is 2%. 2025 was a loss. At the current price you are betting on 2027–2028 CPO customer adoption, not 2026 earnings. The clean entry sits behind 3Q26 ELSFP customer-sample confirmation or a 47,000–50,000 pullback — observation rather than chase.

“The technology is right” and “the price is right today” are different questions. Optical will likely prove to be a real AI-system bottleneck. But if price has already pulled forward several hundred percent, allocator return is determined by where you bought, not by whether the technology was correct.

FAQ

Q: What is CPO in one sentence? A: A new packaging architecture that places the optical engine directly next to the switch ASIC on the same package, dramatically shortening the electrical-signal path and cutting power per bit. Replaces front-panel pluggable optics in high-end AI data-center switches.

Q: Which Korean listed name is genuinely a CPO company? A: OE Solutions (138080.KQ) is the only one with a disclosed CPO-relevant product — its ELSFP external laser source — plus an in-house 100G EML laser chip. It is not yet on Nvidia’s or Broadcom’s public CPO partner list, so the accurate state is “closest candidate,” not “confirmed inclusion.”

Q: Isn’t Daehan Optical Communications a CPO play? A: No. Daehan is a vertically integrated optical-fiber and cable manufacturer (preform → fiber → cable). AI data centers do consume more high-density fiber — that is a downstream beneficiary thesis — but Daehan does not produce CPO core components (optical engines, lasers, photonic ICs).

Q: Should I chase OE Solutions at 53,300? A: Not for a full position. The current price is ~105× 2026E OP. The asymmetric entries are: (a) a pullback into the 47,000–50,000 zone, or (b) confirmation of 3Q26 ELSFP customer samples shipping on schedule. Chasing here is a 30–50bp pilot at most.

Q: Which name is the highest-risk in the cohort? A: Optocore is not investable today (trading suspended on going-concern audit). Daehan Optical is +905% YTD with KRX warning escalation pending. BWE and WooriRo are up several hundred percent on unverified customer bases. None of these are appropriate new entries.

Q: How does this compare to the Korean AI substrate names? A: The substrate cluster has earnings catching up to price, so the actionable trade is selecting validated names at acceptable multiples. The optical cluster has price ahead of earnings, so the actionable trade is filtering signal from thematic noise and waiting for verification points. Same system-BOM thesis, two different stages of the cycle.

Q: When does the case shift from “watchlist” to “core hold” for OE Solutions? A: When two of three confirm: (1) FY26 actually turns to operating profit, (2) 3Q26 ELSFP samples ship plus a customer-qualification mention, (3) Datacom mix moves materially above 2%. Two out of three flips this from observation to position.

This article is for research and informational purposes only and does not constitute investment advice. Price, flow, and earnings data for the seven names were checked against KRX, Hankyung, Alpha Square, and WiseReport. OE Solutions ELSFP and laser-chip details are sourced from official company disclosures (OFC 2026, AI EXPO 2026), the OIF standard documentation, and sell-side reports (iM Securities, Meritz, Hana). Nvidia and Broadcom CPO references are from each company’s investor communications. Optocore is currently suspended on a going-concern audit and is not investable. Daehan Optical Communications is on KRX investment-caution status with warning escalation pending. Analysis can be wrong. Data cut: 2026-05-08–09 KST.

Easy Bio (353810) Analysis: North America Feed Additive M&A at 6x PER and 27-37% ROE

Thu, 07 May 2026 15:00:00 +0900

📄 Part 2 follow-up: Easy Bio Revisited — Korean Feed Stock or Korean Anpario / Phibro? Why the 1Q26 9.4% Margin Print Will Decide the Re-classification — global peer-multiple gap, the 1Q26 OPM verification gate, and the mechanism by which the “feed-stock” label dissolves.

Most Korean feed sector screens return Easy Bio somewhere near the bottom of a sorted list alongside commodity grain processors and integrated poultry operators. The ticker, 353810 on the KOSDAQ, rarely appears in English-language coverage. When it does surface, the framing is almost always “domestic feed company with some specialty exposure.” That framing is roughly three years out of date. As of the third quarter of 2025, feed additives account for 78% of cumulative revenue, and the company’s M&A activity since 2022 has been concentrated entirely in North America, targeting functional coating, sourcing infrastructure, and specialty product lines. The market has not repriced accordingly. The gap between what the business has become and how it continues to be categorized is the central analytical question for any portfolio considering Korean small-cap exposure.

TL;DR

Easy Bio’s revenue is 78% feed additives and 22% conventional feed by cumulative 3Q25 data, yet it screens as a Korean feed stock in most international factor databases.
Three North America acquisitions – Devenish North America, BioMatrix (coating technology, under Pathway USA), and Nutribins (specialty sourcing and product lines, under Devenish) – are assembling what resembles a functional additive distribution and manufacturing platform in Iowa and California.
FY2025 delivered 476.9bn KRW in revenue and 45.0bn KRW in operating profit at 9.43% OPM; FY2026 consensus points toward 510.7bn KRW revenue and 52.5bn KRW operating profit, with ROE estimates ranging from 26.8% (KIRS) to 36.9% (Eugene).
At 7,570 KRW (as of 2026-05-06), market cap is approximately 250.5bn KRW with a forward PER in the 6.2-6.6x range depending on which house’s estimates you use. PBR is 1.79x on trailing book.
Foreign ownership sits at 8.43%, well below what would typically accompany a company with this profitability profile, suggesting the category mismatch is suppressing discovery among international allocators.

Section 1: Business Mix – 78% Additives, Not Generic Feed

The distinction between an animal feed company and a feed additive company matters enormously for valuation. A generic feed operation is a margin-thin logistics exercise: source grain, blend to specification, distribute. Operating margins in conventional compound feed are typically 2-4% in competitive markets. A feed additive business – particularly one focused on functional inputs such as enzyme coatings, gut health compounds, amino acid delivery systems, or specialty mineral formats – operates in a structurally different part of the value chain. Switching costs are higher because additive formulations are often proprietary or semi-proprietary. Customer relationships are stickier because performance claims require validation. And margins reflect that differentiation: specialty additive operators in North America and Europe routinely run OPMs in the 10-15% range for their highest-value product lines.

Easy Bio’s 2025 OPM of 9.43% on a blended basis already speaks to a business that is not commodity feed. The KIRS analyst team, in their January 2026 report, attributed the margin profile directly to the additive segment mix, noting that the 78/22 split in 3Q25 cumulative revenue represented a structural change from the company’s earlier configuration. This is not a marginal tilt toward additives while the legacy feed business remains the engine. The additive segment is now the core business. The feed segment, by volume significant but by margin contribution secondary, provides distribution density and customer relationships that feed the additive cross-sell.

For overseas investors running factor screens, the misclassification risk is real. If Easy Bio is bucketed under “animal feed” rather than “specialty feed ingredients,” it will be compared to KOSDAQ-listed mixed feed producers operating at 3-5% OPM and 8-12% ROE. On those comparables, the current valuation might even look full. Against global feed additive peers – companies like Novus International, Alltech affiliates, or the additive divisions within DSM-Firmenich – the picture inverts. The relevant peer group is running substantially higher multiples on similar or lower ROE profiles.

Section 2: North America M&A – Devenish, BioMatrix, Nutribins

The acquisitions are the thesis in compressed form. Each transaction added something specific, and the three together suggest a deliberate build rather than opportunistic deal flow.

Devenish North America was the anchor. Devenish, originally an Irish agri-nutrition group, had built a presence in the North American market focused on functional feed additives for swine and poultry. The North American division brought established customer relationships with commercial integrators and an operating footprint with scientific credibility around gut health and performance nutrition. For Easy Bio, the acquisition provided immediate revenue at additive margins and a platform onto which subsequent bolt-ons could be attached.

BioMatrix, acquired under the Pathway USA entity, added coating technology. Coating is a technically specific capability: it determines how active ingredients are delivered to the target section of the gastrointestinal tract, protecting sensitive compounds from heat, moisture, and acid degradation during feed processing. Companies with proprietary coating formulations command premium pricing because the coating itself is part of the value proposition, not just the active ingredient inside it. According to the Growth Research report from February 2026, BioMatrix’s Iowa footprint positions it near key swine and poultry production clusters in the US Midwest. The margin ceiling for specialty coated products, where alternatives are limited, has been assessed at above 10% OPM at the product level.

Nutribins, operating under the Devenish umbrella, addressed the sourcing and specialty product dimension. The Eugene analyst report from January 2026 describes Nutribins as contributing high-quality additive sourcing capability and specialty product lines that extend the range Easy Bio can offer through the North America platform. The near-term financial contribution is estimated at 2.0-2.5bn KRW in annual profit, which is modest relative to the total earnings base but meaningful as an incremental add on an already-lean cost structure. The California location of Nutribins complements BioMatrix’s Midwest presence, giving the consolidated North America business bicoastal sourcing and distribution optionality.

The strategic logic of the roll-up is straightforward. North American functional feed additive markets are fragmented. Large integrators and contract growers increasingly prefer consolidated supplier relationships that can offer formulation expertise, coating capability, specialty sourcing, and regulatory support under one roof. Easy Bio, via three acquisitions, has assembled the components of that capability. The question is execution: whether management can integrate these entities operationally, cross-sell across customer bases, and ultimately drive consolidated North America margins toward or above the specialty product ceiling.

Section 3: The Numbers

FY2025 Actuals

FY2025 came in at 476.9bn KRW in revenue and 45.0bn KRW in operating profit, with a 9.43% operating margin. Net income was 29.3bn KRW, producing an EPS of 834 KRW and a trailing ROE of 29.06%. These are not numbers that typically accompany a 6-7x PER on a Korean growth exchange. For reference, the KOSDAQ overall forward PER tends to trade in the 12-15x range for companies with ROE profiles in the 20-30% band.

FY2026 Consensus and House Estimates

Two houses have published detailed FY2026 models with meaningful divergence on the earnings line, which itself reflects differing assumptions about acquisition contribution timing and domestic additive pricing.

Metric	KIRS (Jan 2026)	Eugene (Jan 2026)	Naver Consensus
Revenue (bn KRW)	483.6	510.7	510.7
Operating Profit (bn KRW)	46.4	52.5	52.5
OPM	9.6%	10.3%	10.3%
EPS (KRW)	904	1,252	1,251
Forward PER (at 7,570)	about 8.4x	about 6.0x	about 6.2x
ROE	26.8%	36.9%	34.98%
Analyst Reference Price	–	10,000	10,000

The divergence between KIRS and Eugene on EPS (904 vs. 1,252) is substantial and warrants scrutiny. The Eugene model appears to incorporate more aggressive Nutribins contribution timing and possibly a different tax rate assumption. For a range-based view of valuation, it is more prudent to treat the KIRS and Eugene figures as a bracket rather than averaging toward the midpoint.

Market Snapshot (2026-05-06)

Shares outstanding: 33.08 million. Close price: 7,570 KRW. Market capitalization: approximately 250.5bn KRW (roughly USD 185mn at current rates). Trailing PBR: 1.79x. Foreign ownership: 8.43%.

The market cap figure deserves emphasis because earlier coverage occasionally cited figures near 4,500억원 (450bn KRW), which would imply a share price well above current levels. At 7,570 KRW and 33.08 million shares, the correct market cap is approximately 250.5bn KRW, or 2,505억원. Investors should verify this against real-time data, but the shares outstanding figure from FnGuide/KIRS/Eugene is consistent.

Valuation Range

Using the KIRS earnings estimate of 904 KRW EPS as the conservative anchor and Eugene’s 1,252 KRW as the optimistic scenario, and applying a PER range of 8-12x (which would be modest relative to global specialty feed additive peers), the resulting valuation band spans roughly 7,200-15,000 KRW per share. That range is wide, reflecting genuine uncertainty about acquisition contribution timing and North America integration execution. What it does suggest is that the current price of 7,570 KRW is near or below the lower bound of a range derived from conservative assumptions, not at a premium to realistic scenarios. This is a factor observation, not a price target.

A PBR lens offers a partial check. At 1.79x trailing book, the market is not assigning a deep-value multiple to the balance sheet, but it is not pricing significant intangible value from the North America platform into book either. If the acquisitions compound tangible returns at the ROE levels implied by the consensus (27-37%), book value accretes rapidly, and the PBR anchor becomes less constraining.

Section 4: Why the Discount Exists and What Part May Be Excessive

Several factors explain why Easy Bio trades at a single-digit PER despite the profitability profile. Some are structural, some are transitional, and separating them matters for assessing whether the discount is durable or temporary.

Liquidity and discovery. KOSDAQ small caps with market caps below 300bn KRW are structurally underowned by international investors. The combination of low absolute float (roughly 33 million shares), limited English-language disclosure, and no ADR or dual-listing means that most overseas funds cannot access the stock through standard channels. Foreign ownership at 8.43% reflects this, not any fundamental skepticism about the business. Discovery gaps can persist for years in illiquid small caps.

Acquisition integration risk. Three North America M&A transactions in a relatively short window creates legitimate concern about management bandwidth and integration execution. Korean mid-cap companies acquiring US entities face currency mismatch, cultural and regulatory differences, and the operational complexity of running businesses across twelve time zones. Until Easy Bio demonstrates that the consolidated North America entity is performing at or above acquisition thesis assumptions, some discount to a fully-integrated valuation is rational.

Earnings quality and M&A accounting. Consolidated financials incorporating multiple acquired entities complicate the analysis. Goodwill, purchase price allocation, and intercompany transactions all affect reported margins. The jump in net income between FY2024 and FY2025 will partly reflect acquisition consolidation effects rather than purely organic earnings quality. Investors who cannot distinguish between the two will apply a discount.

Domestic feed segment overhang. The 22% of revenue still generated by conventional feed creates a perception drag. Domestic grain prices, hog and poultry cycle dynamics, and the competitive pressure from large integrated Korean feed operators all affect this segment. Even though it is now a minority contributor, it adds noise to quarterly revenue figures that can distract from the additive story.

The part of the discount that appears excessive, on analytical grounds, is the category mismatch. When a company with 78% specialty additive revenue, 9.4% OPM, and 27-37% ROE is compared to commodity feed companies running 3-4% OPM and 8-12% ROE simply because both appear under “animal nutrition” in a GICS or KSIC sub-industry code, the resulting valuation is not an efficient market outcome. It is a screening artifact. The integration risk and liquidity discount are legitimate. The category error is not.

Section 5: Watch Variables – What Confirms or Weakens the Thesis

The investment thesis for Easy Bio rests on a specific set of testable propositions. Monitoring these variables provides a more structured approach than tracking the share price in isolation.

1Q26 Operating Margin – The Near-Term Inflection Signal

Eugene’s model forecasts 1Q26 operating profit of 11.8bn KRW. On the FY2026 revenue trajectory, that implies a quarterly OPM approaching 9.4% or higher in the first quarter. The KIRS model’s FY2026 OPM assumption of 9.6% and Eugene’s 10.3% both depend on the North America entities contributing at or near their modeled run rates from early in the year. If 1Q26 OPM comes in below 8.5%, it would suggest that acquisition consolidation is taking longer than modeled, or that domestic feed margins are compressing faster than expected. An OPM above 9.4% in 1Q26 would provide the first evidence that the FY2026 path toward 10% is on track.

North America Revenue Disclosure

Easy Bio does not currently break out North America segment revenue explicitly in English-language filings. As the acquisition platform matures, any move toward geographic segment disclosure would allow analysts to track North America revenue growth and margins independently from the Korean additive and feed base. Watch for any regulatory filings or IR materials that begin to distinguish domestic versus international additive contribution.

BioMatrix Coating Product Adoption

The thesis for BioMatrix is that proprietary coating technology creates pricing power in North American swine and poultry markets. This plays out over customer validation cycles, typically 12-24 months for large commercial integrators. Evidence of new customer wins or contract renewals with expanded product inclusion would confirm the coating technology thesis. The absence of such evidence two years post-acquisition would raise questions about competitive differentiation.

Nutribins Profit Contribution

The Eugene estimate of 2.0-2.5bn KRW in annual profit from Nutribins is a trackable claim. If FY2026 net income runs toward the high end of the 43-44bn KRW consensus and the domestic Korean business performs in line with prior years, the residual should approximate the North America contribution. Significant shortfalls at the net income line without an identifiable domestic explanation would point to underperformance in the acquired entities.

Margin Trajectory Toward 10% OPM

The clearest confirmation of the specialty additive re-rating thesis is a sustained move in consolidated OPM toward and above 10%. KIRS models 9.6% for FY2026; Eugene models 10.3%. Historical North American functional additive businesses running specialty coated products at scale carry OPMs above 10% at the product level. The consolidated blended margin will be lower because of the domestic feed segment. But if the additive mix continues to grow as a share of revenue, and if North America specialty products carry the margin premium that Growth Research’s February 2026 report suggests is achievable where alternatives are limited, the path to 10%+ consolidated OPM exists structurally. Failure to approach 10% OPM by FY2027 would suggest either that the North America specialty products are more commoditized than modeled, or that integration costs are permanently elevated.

Foreign Ownership and Liquidity

At 8.43%, foreign ownership is low enough that even a modest increase driven by discovery from international fund screens could provide a meaningful demand catalyst. Watch for any change in MSCI or FTSE Russell index inclusion status that might mechanically increase index-linked foreign demand. Conversely, if domestic institutions reduce position sizes while foreign ownership remains flat, it would signal domestic skepticism about execution rather than international indifference.

FX Sensitivity

Easy Bio’s North America revenue is denominated in USD. The Korean won/US dollar rate affects reported KRW revenue and margins from those entities. A sustained won strengthening beyond 1,300 KRW/USD would create a headwind to reported consolidated revenue even if underlying North America performance is on track. This is a reversible factor and not a thesis-breaker, but it can cause quarterly reported numbers to diverge from underlying business performance and should be adjusted for when reading earnings.

Final Note

Easy Bio is a case study in why category labels matter for equity valuation and why Korean small-cap stocks in particular are prone to structural undervaluation when English-language analytical coverage is thin. The company has rebuilt its revenue mix, acquired three North American assets with distinct and complementary functional roles, and delivered FY2025 results that most investors would associate with a mid-tier specialty chemicals or life science company rather than a feed stock. The market cap sits at approximately 250.5bn KRW on a business generating 27-37% ROE depending on which house’s model you use. The forward PER of 6.2-6.6x reflects a discount that is partly justified by integration risk and liquidity constraints, and partly a screening error that has not yet been arbitraged away.

For overseas investors building a position in Korean equities with exposure to the global protein supply chain, Easy Bio sits in a structural gap that is analytically interesting: too small for most institutional mandates, too specialized for generic Korea ETF inclusion, and too early in its North America build to have produced the multi-year track record that systematic allocators require. These characteristics describe the discount. Whether they describe a permanent condition or a transitional one depends on the watch variables outlined above, and most critically on what 1Q26 earnings reveal about North America integration momentum and the trajectory toward 10% OPM.

The data in this analysis is sourced from KIRS (January 2026), Eugene (January 2026), Growth Research (February 2026), and Naver/Kiwoom market data as of 2026-05-06. Cross-referencing directly with company filings on the DART system and any subsequent quarterly disclosures is the appropriate next step before forming a portfolio view.

Korean Quality-Compounder Screen — Only 4 Names Pass 9 Filters: VM, Pamicell, Silicon2, Samyang Foods (And Why Pamicell Survives Both Screens)

Thu, 07 May 2026 08:30:00 +0900

🔗 Related: Earnings-Explosion Screen — 67 Names · Korea Daily Market Hub

The previous post showed an “earnings explosion” screen returning 67 names with the lesson “most have already moved.” This piece runs the inverse experiment: stack filters to the limit and see what actually clears. Nine simultaneous conditions — ROE ≥25%, revenue growth ≥+15%, OP growth ≥+20%, OPM ≥10%, P/E ≤25×, target headroom ≥+15%, daily turnover ≥₩3.0bn, foreign+institution net-buy, RSI <75 — and only four Korean equities pass.

Executive Summary

Only four names clear the nine simultaneous filters: VM, Pamicell, Silicon2, Samyang Foods. Out of the entire Korean listed universe. The narrowness of the result is the point.
The formula targets the intersection of “good business” and “what the market is currently buying.” ROE ≥25% catches efficient-capital users; P/E ≤25× catches names not yet expensively priced; foreign+institution net-buy catches names with active flow support. When all three filter dimensions clear simultaneously, quality, price, and flow are confirmed in one cohort.
Pamicell survives both screens. It cleared the previous earnings-explosion screen of 67 names and this 9-filter screen of 4 names. ROE 38%, OPM 36.3%, OP growth +72.3%, foreign+institution 20D +₩53.7bn. Two independent screening lenses, same conclusion — the strongest single signal in this cohort.
Silicon2 has the cleanest quality-vs-price combination. ROE 38.7%, P/E 13.3×, target headroom +36.8%. Among the four, the price-relative-to-quality combination is the cleanest. But its current leadership intensity is below Pamicell’s.
VM ranks #1 on raw quant but with elevated late-stage volatility risk. OP growth +242.9%, P/E 19.8×, target headroom +29.8%. On numbers alone the strongest. But +451% off 52-week low is “already-moved” territory — a tactical/aggressive holding rather than a core position.
The narrow-miss list is the more interesting research output. HD Hyundai Marine Engine (P/E 25.7×, missed by 0.7×), Classys (only flow filter failed), PharmaResearch (only flow filter failed), Isu Petasys (P/E too high), Samsung Electronics (RSI too high). One condition flips and these names enter — useful “watch list” candidates.

1. Why ROE 25% — The Foundation of the Screen

1.1 The One-Line Definition

ROE 25% means: for every ₩100 of equity, the company generates ₩25 of net income annually. In plain terms, capital is being deployed very efficiently.

1.2 Why This Is a Strong First Filter

ROE ≥25% carries three implications:

Implication	Read
High capital efficiency	Modest equity base, large absolute earnings
Reinvestment value	Re-deployed earnings compound the equity base
Multiple justification	Higher P/E or P/B has analytic basis

The critical question is whether the ROE is sustainable. A single year of ROE 25% is meaningless. To be a “good ROE,” it has to hold for 2–3+ years, be accompanied by revenue growth, and not depend on leverage.

1.3 Good ROE 25% vs Bad ROE 25%

Good ROE 25%	Bad ROE 25%
Comes with revenue growth	Revenue is flat; only NI spikes
OPM is high	Debt-driven ROE inflation
Sustainable across 2–3+ years	One-year peak from a cyclical top
Reinvestable market is large	One-off (asset sale, FX gain, divestiture)
P/E / P/B is justifiable vs growth	P/B ≥10× already, no headroom

That distinction matters. ROE ≥25% by itself is a first-filter for “good-business candidates,” not a buy signal. A real buy decision requires growth durability, valuation, flow, and chart position — which is exactly why the screen stacks nine filters.

2. The Nine Filters — Why Stack Them

2.1 The Formula

① ROE ≥ 25%
② 2026F revenue growth ≥ +15%
③ 2026F OP growth ≥ +20%
④ 2026F OPM ≥ 10%
⑤ 2026F P/E ≤ 25×
⑥ Target-price headroom ≥ +15%
⑦ 20-day average turnover ≥ ₩3.0bn
⑧ Trailing 20-day foreign + institution net-buy
⑨ RSI < 75 (or 20-day MA pullback confirmed)

2.2 What Each Filter Catches and Filters Out

Filter	Catches	Filters out
① ROE ≥25%	High capital-efficiency businesses	Profit-poor businesses
② Revenue ≥+15%	Top-line-growing businesses	ROE-from-cost-cutting / one-offs
③ OP ≥+20%	Earnings leverage	Top-line growth without margin lift
④ OPM ≥10%	Pricing power	Low-margin top-line expansion
⑤ P/E ≤25×	Not yet expensively priced	Already-discounted-future-expectations
⑥ Target headroom ≥+15%	Reward room remains	At or near target price
⑦ Turnover ≥₩3.0bn	Tradable	Ultra-small-cap illiquidity
⑧ Foreign+institution net-buy	What the market is currently buying	Where smart money is exiting
⑨ RSI <75	Not yet overheated	Short-term overbought

2.3 The Core Insight Behind Stacking

When all nine clear simultaneously, three independent dimensions confirm at once:

Quality: ROE + OPM + revenue/OP growth
Price: P/E + target headroom
Market validation: foreign+institution flow + RSI + turnover

A “good business” (quality) that is “not yet expensively priced” (price) and “currently being bought” (market validation) — the intersection.

The fact that nine simultaneous filters are hard to clear is itself the value. Where the earnings-explosion screen returned 67, this screen returns 4. Strict filters produce meaningful results.

3. The Four That Pass

Rank	Name	ROE	P/E	OP growth	OPM	Target hd	20D return	Foreign+Inst 20D	Profile
1	VM (KOSDAQ: 081000)	34.2%	19.8×	+242.9%	29.4%	+29.8%	+42.2%	+₩25.1bn	Aggressive momentum
2	Pamicell (KOSPI: 005690)	38.0%	21.1×	+72.3%	36.3%	+21.9%	+36.7%	+₩53.7bn	Focus candidate
3	Silicon2 (KOSDAQ: 257720)	38.7%	13.3×	+30.3%	18.0%	+36.8%	+15.1%	+₩31.7bn	Quality candidate
4	Samyang Foods (KOSPI: 003230)	35.3%	18.8×	+31.7%	23.4%	+38.2%	+7.1%	+₩16.3bn	Steady compounder

All four share ROE 34–39%, OPM 18–36%, foreign+institution net-buy. Common: capital efficiency + earnings growth + active flow. Differences are character.

4. Per-Name Read

4.1 Pamicell — The Cross-Screen Survivor

Why Pamicell is the practical #1: it cleared the previous earnings-explosion screen of 67 and this 9-filter screen of 4. Two independent screening lenses, same conclusion.

ROE 38.0% → top-tier capital efficiency
OPM 36.3% → highest margin among the four
OP growth +72.3% → earnings leverage confirmed
P/E 21.1× → not yet expensively priced
Foreign+Inst 20D +₩53.7bn → flow strongest in cohort

Pamicell was already analyzed in Series Part 3 with a GARP Score of 150 (top of the materials-stock universe). The fact that it also clears this independent ROE-25%-multi-factor screen means the appeal holds across very different filter logic — quality + price + flow as a distinct lens from the original GARP composite.

That said, 20-day return +36.7% raises near-term overheating risk. The right posture is “wait for pullback or scale in after 1Q earnings confirm” rather than “full conviction now.”

Tracking signals:

₩19,000–20,000 holding as support (on pullback)
1Q26 OP ≥₩11.5bn with OPM ≥30%

4.2 Silicon2 — Cleanest Quality-vs-Price

Silicon2 has the cleanest combination of capital efficiency relative to multiple in the cohort.

ROE 38.7% → highest ROE of the four
P/E 13.3× → cheapest of the four
Target headroom +36.8% → second-highest in cohort
20D +15.1% → most stable of the four (not overheated)

ROE 38.7% with P/E 13.3× is rare in the Korean market. When ROE is this high but P/E sits at 13×, the market is either (a) skeptical that the ROE is sustainable, or (b) hasn’t fully discovered the name yet.

Silicon2 is a global K-beauty distribution platform. Strong overseas-revenue mix and good margins. But distribution-business dynamics — freight, FX, margin variability — matter. If the market’s P/E 13× reflects “distribution-business discount,” that’s defensible; if it reflects “growth deceleration concern,” it warrants caution.

Recent leadership intensity is weaker than Pamicell’s. 20D +15.1% is steady but not the strongest mover. Closer to “high-quality name that can move again” than “currently leading.”

Tracking signals:

₩41,500–43,000 holding as support (on pullback)
2026F OP growth ≥+20% maintained
Freight / margin pressure not materializing

4.3 VM — Best Quant Score, Highest Variance

On quant alone, VM is the strongest of the four.

OP growth +242.9% → dominant #1 in cohort
OPM 29.4% → second highest
P/E 19.8× → reasonable
Target headroom +29.8% → adequate
Foreign+Inst 20D +₩25.1bn → solid

The issue is price location. 52-week-low to current: +451%. A 4.5×-in-a-year run. This isn’t “undervalued discovery” — it’s “already-moved territory.”

OP growth +242.9% may carry “turnaround base-effect” character. If 2025 OP was depressed, even modest absolute lift produces a large growth rate. Whether the growth is “structural” or “base effect” is the analytical question.

VM is more of an aggressive position than a core hold. Upside is meaningful when right; if wrong, the +451%-off-low position implies large downside.

Tracking signals:

₩52,000–55,000 pullback support
Order-momentum maintained
2026F OP estimate revisions

4.4 Samyang Foods — Solid Compounder, Not the Current Leader

Samyang Foods clears all nine on numbers.

ROE 35.3% → high
OPM 23.4% → strong
P/E 18.8× → reasonable
Target headroom +38.2% → highest in cohort

A genuinely strong business with a clean narrative — Buldak ramen global expansion, rising overseas-revenue share, margin expansion.

But 20D +7.1% is the weakest of the four. In the current market regime where momentum-leadership matters, Samyang isn’t on the front line. A portfolio-stability slot, not a short-term-momentum slot.

Tracking signals:

₩1.25M–1.30M pullback for entry consideration
Overseas growth not decelerating
OPM peak-out check

5. The Near-Miss List — Where the Real Optionality Sits

Name	Disqualifier	Failed condition	Read
HD Hyundai Marine Engine	P/E 25.7×	⑤ P/E ≤25×	0.7× miss. Effectively at-pass
Classys	Foreign+Inst net-sell	⑧ Net-buy	Single-flag: flow recovery → in
PharmaResearch	Foreign+Inst net-sell	⑧ Net-buy	Pullback-style quality. Flow confirmation needed
Isu Petasys	P/E 41.4×, target +10.5%	⑤⑥ P/E + target	Leader, but priced
Samsung Electronics	RSI >75	⑨ RSI	Hold OK; new entry per filter blocked

The near-miss list is more interesting than it looks because a single condition relaxation puts each one in the active cohort.

HD Hyundai Marine Engine is 0.7× away. In an aggressive-market regime where the P/E filter is loosened from 25× to 30×, it enters. Classys and PharmaResearch enter the moment flow turns positive. Samsung Electronics enters when RSI cools to <75.

Tracking these “waiting candidates” is part of the screen’s value.

6. The Cross-Screen Intersection — Where 67 Meets 4

The previous post returned 67 names from the earnings-explosion screen. This post returns 4 names from the ROE-25%-9-filter screen. Cross the two — and Pamicell appears in both.

[Earnings-explosion screen — 67 names]
Conditions: 2025/2026 profit + OP/NI each ≥+80%
Result: 67 → most already moved
Pamicell: ✓ pass (GARP Score 150)

[ROE-25% screen — 4 names]
Conditions: ROE ≥25% + growth + P/E ≤25× + flow + RSI
Result: 4 → quality+price+flow intersection
Pamicell: ✓ pass (ROE 38%, OPM 36.3%, flow +₩53.7bn)

Cross-screen result:
→ Pamicell survives both lenses with the same conclusion
→ The "earnings explosion" growth lens AND the "ROE+price+flow" quality lens both confirm

This is why cross-screen analysis is more meaningful than any single screen. A single filter creates confirmation bias; two independent filters provide robustness.

Whether Silicon2, VM, and Samyang Foods also cleared the earnings-explosion screen is a separate cross-check. The fact that Pamicell appears in both is, by itself, the strongest analytical signal in this cohort.

7. Two Honest Caveats

7.1 All Four Names Have Recently Run

VM: +451% from 52-week low; 20D +42.2%
Pamicell: +105% from 52-week low; 20D +36.7%
Silicon2: 20D +15.1% (relatively stable)
Samyang Foods: 20D +7.1% (relatively stable)

VM and Pamicell are up 35–42% in 20 sessions. The screen flagged all four at the screening moment, but at already-elevated prices, “full conviction now” is inefficient. Pullback wait or post-earnings entry is the cleaner setup.

7.2 The Screening Formula Itself Can Be Wrong

These nine conditions are not an absolute formula. Several traps:

ROE may be temporary: a strong 2025 ROE that drops in 2026 is meaningless
Consensus estimates can revise: 2026F OP-growth is a sell-side estimate, and estimates can be wrong
Flow can reverse: today’s foreign+institution net-buy can become tomorrow’s net-sell
RSI <75 is a snapshot: the next day’s print may be ≥75

The screen is “look at this name more deeply,” not “buy this name.” That four cleared means “worth a closer look,” not “guaranteed buy.”

8. Tracking Signals — Four Names + Watch List

8.1 Pamicell (Focus Candidate)

₩19,000–20,000 holding as support
1Q26 OP ≥₩11.5bn with OPM ≥30%
Same tracking variables as Series Part 3

8.2 Silicon2 (Quality Candidate)

₩41,500–43,000 holding as support
2026F OP growth ≥+20% maintained
Freight / margin pressure not materializing

8.3 VM (Aggressive)

₩52,000–55,000 pullback support
Order momentum maintained
2026F OP estimate revisions

8.4 Samyang Foods (Steady-Compound Watch)

₩1.25M–1.30M pullback for entry consideration
Overseas growth not decelerating
OPM peak-out check

8.5 Watch List

HD Hyundai Marine Engine: when P/E moves below 25×
Classys / PharmaResearch: when foreign+institution flow turns to net-buy
Samsung Electronics: when RSI cools to <75

9. The Single Closing Line

ROE ≥25%, revenue growth ≥+15%, OP growth ≥+20%, OPM ≥10%, P/E ≤25×, target headroom ≥+15%, daily turnover ≥₩3.0bn, foreign+institution net-buy, RSI <75. Stack nine simultaneous filters and only four Korean names clear: VM, Pamicell, Silicon2, Samyang Foods.

If the prior post’s 67-name earnings-explosion screen taught “most have already moved,” this 4-name screen teaches “strict filters surface what actually compounds.” Sixty-seven is too many — the market has discovered most. Four is few enough to matter.

The four share efficient capital deployment, growing earnings, and active flow. Their differences are in character: Pamicell is the focus candidate (cleared both screens, ROE 38%, OPM 36.3%, flow +₩53.7bn); Silicon2 is the quality candidate (ROE 38.7% with P/E 13.3× — best quality-vs-price); VM is the aggressive position (OP growth +243%, dominant on pure quant, but +451% off low); Samyang Foods is the steady compounder (clean numbers, but not the current momentum leader).

Pamicell surviving both screens is the strongest analytical signal in this cohort. Two independent filtering logics — earnings-explosion growth and ROE+price+flow quality — produce the same answer.

That said, all four have recently run hard. The screen result is not a “full-conviction-now” signal. Pullback wait or post-earnings entry is cleaner. The narrow-miss watch list (HD Hyundai Marine Engine, Classys, PharmaResearch, Samsung Electronics) is also worth tracking — relax one filter and any of them enters.

The screen is the start, not the destination. Whether the four names print 67 or 4, the next step is asking why each one cleared and whether that clearance is sustainable.

FAQ — Korean Quality-Compounder Screen May 2026

Q: How many Korean stocks pass a strict 9-filter ROE-25% screen? A: As of May 7, 2026: only 4 names — VM (KOSDAQ 081000), Pamicell (KOSPI 005690), Silicon2 (KOSDAQ 257720), Samyang Foods (KOSPI 003230). The criteria stack ROE ≥25%, revenue growth ≥+15%, OP growth ≥+20%, OPM ≥10%, P/E ≤25×, target headroom ≥+15%, daily turnover ≥₩3.0bn, foreign+institution net-buy, RSI <75.

Q: Why does ROE 25% matter as a screening threshold? A: ROE 25% means the company generates ₩25 of net income per ₩100 of equity per year — a strong indicator of capital-deployment efficiency. Stacked with growth (revenue / OP / margin), valuation (P/E / target), and flow (foreign+institution / RSI) filters, it isolates “good business + reasonable price + active market support” simultaneously.

Q: Why does Pamicell stand out in this cohort? A: Pamicell cleared both the previous earnings-explosion screen (67 names) and this ROE-25% screen (4 names). Two independent filtering logics produced the same answer, which is the strongest analytical signal in either screen. ROE 38%, OPM 36.3%, OP growth +72.3%, foreign+institution 20D +₩53.7bn.

Q: Is Silicon2 (257720) publicly traded? A: Yes — Silicon2 is listed on KOSDAQ under ticker 257720. It is a global K-beauty distribution platform with high overseas-revenue mix and ROE 38.7%. Its P/E 13.3× combined with ROE near 39% is unusually clean quality-vs-price math by Korean-market standards.

Q: What is VM (081000)? A: VM is a KOSDAQ-listed Korean equipment / industrial-products company that cleared the screen with the strongest pure quant score (OP growth +242.9%). However, it has run +451% off its 52-week low, putting it firmly in “already-moved” territory — closer to an aggressive position than a core hold.

Q: Why is Samyang Foods (003230) listed but flagged as steady-compounder? A: Samyang Foods (KOSPI 003230) clears all nine filters with strong fundamentals (ROE 35.3%, OPM 23.4%, P/E 18.8×). However, its 20-day return at +7.1% is the lowest in the cohort, meaning it is not currently the market’s momentum leader — making it a steady-compound portfolio slot rather than a short-term-momentum slot.

Q: Should I just buy all four screen passes? A: No. The screen is “worth a closer look,” not “guaranteed buy.” Four key caveats: ROE may be temporary, consensus estimates can revise, flow can reverse, and RSI <75 is a snapshot. Two of the four (VM and Pamicell) are up 35–42% in 20 sessions — pullback wait or post-earnings entry is cleaner than chasing.

Q: Why is the near-miss list (“HD Hyundai Marine Engine, Classys, PharmaResearch”) interesting? A: Each missed by exactly one condition. HD Hyundai Marine Engine: P/E 25.7× (0.7× miss). Classys / PharmaResearch: foreign+institution net-sell (only flow filter failed). One condition flips and they enter the active cohort. This makes them productive watch-list candidates.

This post is research and commentary only, not investment advice. The 9-filter screen formula, per-name ROE / P/E / OPM / growth figures, and flow data are sourced from local DB, sell-side consensus, and public materials and reflect analyst inference at the screening moment (2026-05-06). Subsequent price / flow / earnings changes can change results. Short-selling, lending, and program-flow data are not confirmed for the local DB. The screen is an analytical starting point, not a buy signal. Analysis can be wrong. Data as of May 6–7, 2026 KST.

Korean Earnings-Explosion Screen May 2026 — 67 Names Found, Most Already Moved: Where the Residual Alpha Sits (QRT, BCnC, Wirenet)

Thu, 07 May 2026 08:00:00 +0900

🔗 Related reads: Korea Daily Market Hub · Korean Semis Rally May 6 · Korea Semiconductor HBM Hub

Screening Korean equities on (2025 OP > 0) ∧ (2025 NI > 0) ∧ (2026F OP > 0) ∧ (2026F NI > 0) ∧ (2026F OP growth ≥ +80%) ∧ (2026F NI growth ≥ +80%) produces 67 hits. The interesting fact: most have already moved. The harder analytical question is not “which screen output should I buy?” but “where in the 67 does residual alpha still live, and why?” This piece anchors that question with FnGuide as the “after-discovery” reference case, then runs a depth pass on the three names with the most distinct under-discovered profile: QRT (semiconductor reliability validation), BCnC (substrate-materials localization), and Wirenet (5G-SA transmission equipment).

Executive Summary

The screen returned 67 names — most have already moved. Even with strict criteria (2025 profit + 2026 profit + ≥+80% YoY OP and NI growth), 67 Korean listed names cleared. More than half are up >+50% YTD. The screen does not by itself produce alpha; the market has already discovered most of these names.
FnGuide demonstrates the “after-discovery” regime most dramatically. Year-start P/E 10× and P/B 1.4× → May P/E 38× and P/B 5.45×. Total return YTD +279%. A genuinely strong business — Korea’s data / index / financial-information infrastructure with effectively monopolistic positioning, 2025 OPM 30%, ROE 15%. But at today’s price, the stock is no longer “cheap-and-buy” — it now requires 2026 OP ~₩20.0bn to be sustained. Even on May 6’s surge, foreigners and institutions both net-sold.
Among the 67, the relatively under-moved cohort: QRT (YTD +27–42%), BCnC (+26–33%), Tech Wing (+22%), STI (+20%), DI (+47%), Devsisters (-35%), Alteogen (-21%). “Up less” is not the same as “undervalued” — it can be a discount-for-reason. Distinguishing the two is the actual analytical work.
Three-name deep-dive priority: QRT > BCnC > Wirenet. QRT carries a structural thesis (“the more complex semis become, the more validation is the bottleneck”) that fires across AI / HBM / CXL / RF / space — a multi-vector thesis. BCnC has a clean materials-localization narrative but P/E 42× with ROE 6.4% — price has run ahead of capital efficiency. Wirenet is up +118% YTD with foreign net selling — the market has already discovered it; further alpha requires confirmation, not discovery.
The takeaway about screening itself: the screen is the start, not the destination. 67 hits but most already moved. Alpha lives in “speed-of-market-discovery vs gap-still-remaining,” which is a separate question from “what passed the screen.”

1. The Screen — What It Found

1.1 Criteria and Output

Criteria:
 - 2025 operating profit > 0
 - 2025 net income > 0
 - 2026F operating profit > 0
 - 2026F net income > 0
 - 2026F OP growth ≥ +80%
 - 2026F NI growth ≥ +80%

Result: 67 names cleared

Sixty-seven is a lot. The natural question — “are this many Korean companies really printing earnings explosions?” — has a structural answer: 2025–2026 sees simultaneous up-cycles in semiconductors, AI infrastructure, energy transition, and materials. So even strict criteria yield a large cohort.

1.2 The 67-Name YTD Distribution — Most Already Moved

Sorting the cohort by year-to-date return reveals the most important observation in the entire piece.

YTD bucket	Approx. count	Representative names
≥ +200%	5+	Joosung Engineering (+319%), HD Hyundai Energy (+286%), FnGuide (+279%), Amotech (+215%)
+100% to +200%	15+	Daeduck Electronics (+162%), SK Hynix (+137%), Kolon Industries (+125%), Wirenet (+112%), Samsung Electronics (+107%)
+50% to +100%	15+	Korea Circuit (+99%), Hooseong (+91%), Nano (+88%), Dongwoon Anatech (+74%), Wonik IPS (+61%)
+0% to +50%	20+	QRT (+27–42%), BCnC (+26–33%), Tech Wing (+22%), STI (+20%), Robotis (+15%)
Negative	6	Devsisters (-35%), Astera Sys (-22%), Alteogen (-21%), SBS (-17%)

The single-line read: more than half of the 67-name cohort is already up >+50% YTD. Treating “the screen output” as a buy list is structurally late.

1.3 The Under-Moved Subset — Where Residual Alpha Could Sit

The +0% to +50% bucket and the negative bucket are where residual alpha could still be sitting. But “up less” is not the same as “undervalued” — it can be a justified discount.

Best-positioned candidates from this group:

Name	YTD	2026F OP	OP growth	2026F P/E	Why under-moved?
QRT	+27–42%	₩10.8bn	+125%	33.3×	Semiconductor validation isn’t yet recognized as a “theme”
BCnC	+26–33%	₩10.9bn	+180%	42.0×	Materials-localization story is good, but ROE 6.4%
Tech Wing	+22%	—	—	—	Quiet semi-test-equipment earnings story
STI	+20%	—	—	—	Semi equipment / parts
Devsisters	-35%	—	—	—	Game-segment decline followed by turn — low market interest
Alteogen	-21%	—	—	—	Biotech price correction vs expectations

Three names sit on top of this for a depth pass: QRT, BCnC, Wirenet. (Wirenet is included from the +100–200% bucket because it represents the contrasting “already discovered” case.)

2. FnGuide — The “After-Discovery” Reference Case

Before the three-name deep dive, FnGuide is the cleanest reference case for what “earnings explosion meets market discovery” looks like in the regime where the screen has done its work.

2.1 Year-Start to Today

Date	Close	TTM P/E	TTM P/B	2026F P/E
Jan 2	₩8,690	10.0×	1.44×	5.1×
Feb 27	₩20,400	23.6×	3.38×	12.0×
Apr 30	₩27,200	31.4×	4.50×	16.0×
May 6	₩32,900	38.0×	5.45×	19.4×

In five months, P/E expanded from 10× to 38× and P/B from 1.4× to 5.45×. Total return YTD +279%.

2.2 Why It Re-Rated

FnGuide is a genuinely strong business.

Business: Korean financial data / index / information-services infrastructure
2025 financials: revenue ₩35.4bn, OP ₩10.7bn, OPM 30.1%, ROE 15.1%
2026F (Naver consensus): revenue ₩49.6bn (+40%), OP ₩20.4bn (+91%), OPM 41.1%

A scarce data-infrastructure operator embedded in domestic financial workflows. Low debt, high margin, recurring revenue. In an “AI as electricity, data as oil” era, FnGuide owns the oil.

At year-start P/E 10×, FnGuide was an “unknown quality compounder.” Today’s P/E 38× is what happens when the market discovers that fact.

2.3 Today’s Price Is Not “Cheap-and-Buy”

The price math reveals the after-discovery regime:

Korea IR Council estimate (2026-02-19):
 2026F revenue ₩41.4bn, OP ₩13.3bn, EPS ₩1,043
 → Current-price P/E = 32,900 / 1,043 = 31.5×

Naver consensus:
 2026F revenue ₩49.6bn, OP ₩20.4bn, EPS ₩1,700
 → Current-price P/E = 32,900 / 1,700 = 19.4×

Verifications:

Korea IR P/E = 32,900 / 1,043 = 31.55× ≈ 31.5× ✓
Naver P/E = 32,900 / 1,700 = 19.35× ≈ 19.4× ✓

The two estimates have a wide spread (OP ₩13.3bn vs ₩20.4bn). For the current price to be “fair,” the aggressive Naver estimate has to print. On the conservative Korea IR estimate, P/E 31.5× is already expensive.

Even on May 6’s broad-market surge, FnGuide saw foreign -₩750m and institution -₩220m net selling. Flow confirmation is weak.

2.4 Four Lessons FnGuide Embeds

[Lesson 1] Earnings explosion + good business + low-multiple = strong re-rating
 → Year-start P/E 10× → May P/E 38× in 5 months

[Lesson 2] After re-rating, the stock turns into "an earnings-must-print stock"
 → Today's price requires 2026 OP \~₩20bn

[Lesson 3] Finding it via screening can already be late
 → Buying YTD +279% as "earnings explosion" is buying near the top

[Lesson 4] Alpha lives "before discovery"
 → FnGuide's January P/E 10× was the alpha zone; May P/E 38× isn't

These four lessons frame the next three names. “Earnings explosion + relatively under-moved” means either “market hasn’t discovered yet” or “discovered but discount-for-reason.” Distinguishing the two is the substance of the analysis.

3. QRT (KOSDAQ: 405100) — The More Complex Semis Get, the More Validation Is the Bottleneck

3.1 Business

QRT in one line: a Korean semiconductor reliability-validation specialist. Not a chip maker — a company that validates whether chips work correctly.

Hanyang Securities frames QRT as “a validation platform performing reliability assessment and comprehensive analysis simultaneously.” KB Securities classifies it as “Korea’s domestic semiconductor reliability validation company.”

The reason this matters: the more complex semiconductors get, the more validation becomes the bottleneck.

AI chips get more complex → HBM stacks get taller → CXL connections get added
→ RF / communication-chip frequencies climb → space-bound chips need radiation hardening

Every "more complex" axis demands reliability validation.
Without validation, mass production cannot start.
The number of companies capable of doing this validation is constrained.

→ QRT's position: the bottleneck operator of this validation

3.2 Numbers

Item	Value
May 6 close	₩22,500
YTD	+41.5%
20-day return	+50.5%
RSI(14)	63.6
2026F revenue	₩83.5bn
2026F OP	₩10.8bn
2026F OPM	12.9%
2026F P/E	33.3×
OP growth	+125%

Hanyang Securities estimates 2026F revenue ₩85.0bn, OP ₩9.45bn. Local DB OP ₩10.8bn appears to average across sources. Either way, OP ~₩10bn is the core 2026 verification line.

A recently-disclosed MOU with Hyperaccel for AI-chip product-development and mass-production quality cooperation is constructive — but an MOU is not revenue.

3.3 Why QRT Ranks #1 Among the Three

The structural advantage is straightforward:

[BCnC] semi materials → competitors exist; substitution is possible
[Wirenet] telecom equipment → project revenue with high quarterly volatility
[QRT] semi validation → demand grows as chips get more complex; validation capacity is hard to scale short-term

Distinction:
- Materials can be substituted (rivals, imports)
- Equipment can be delayed when projects are delayed
- Validation requirement scales with chip complexity, and validation capacity isn't quickly added

The thesis “the more complex semis get, the more validation is the bottleneck” fires across AI, HBM, CXL, RF, and space — every direction. Whichever vector wins, QRT benefits.

3.4 P × Q × C

Factor	Read
P (price)	More complex tests on AI / HBM / CXL / RF / space command higher unit pricing
Q (volume)	Customers, product families, validation items expand (AI, RF, space, autonomous driving)
C (cost)	Equipment-utilization rise + analysis-headcount leverage drive OPM up

3.5 Honest Caveats

P/E 33.3× is not cheap. The screen flagged QRT as “earnings explosion” but price has already moved.
20-day return +50.5% raises short-term overheating risk. RSI 63.6 isn’t yet overbought, but it’s getting close.
An MOU is not revenue. Whether actual validation contracts print in quarterly results is the first verification.
OP ~₩10bn is the entire accounting basis of the thesis. Below ₩9bn, the thesis weakens.

3.6 Tracking Signals

2026F OP ~₩10bn confirmed in actual results
RF / space-bound equipment revenue actually printing
OPM 12–13% maintained or rising
Hyperaccel MOU converting into actual orders
₩20,500–21,200 holding as support (on pullback)

4. BCnC (KOSDAQ: 146320) — Localization Story Is Strong, Price Is Ahead of Earnings

4.1 Business

BCnC manufactures consumable parts (quartz, silicon, ceramic) for semiconductor etch and deposition processes. The core thesis is localization of synthetic quartz (QD9 / QD9+) and silicon (SD9+).

Semi etch process
→ quartz / silicon / ceramic parts are consumed
→ requires periodic replacement (consumable-by-nature)
→ localization replaces imports + improves margin

BCnC's positioning:
QD9+ synthetic quartz = replaces imported quartz
SD9+ silicon = replaces imported silicon
CD9 ceramic = next-gen material

2025 revenue mix: synthetic quartz QD9 / QD9+ 67%, natural quartz 17%, others. Localization of QD9+ / SD9+ / CD9 is the margin-improvement driver.

4.2 Numbers

Item	Value
May 6 close	₩18,070
YTD	+33.2%
20-day return	+44.1%
RSI(14)	65.1
2026F revenue	₩106.2bn
2026F OP	₩10.9bn
2026F OPM	10.3%
2026F P/E	42.0×
OP growth	+180%
ROE	6.4%

4.3 The Problem: P/E 42× × ROE 6.4%

This is the central weakness.

Materials-localization story: good
OP growth +180%: good
QD9+ first overseas-customer PO: good

But:
P/E 42× + ROE 6.4% = price has run ahead of earnings

For P/E 42× to be justified, 2027 earnings leverage has to be materially stronger than 2026’s. 2026 OP ₩10.9bn would need to scale to >₩20bn in 2027 for the multiple to look “fair.” That trajectory is not yet confirmed in sell-side consensus.

ROE 6.4% is also a burden. Low ROE means earnings aren’t fully utilizing the capital base. Materials-localization needs to drive margin to a level where ROE moves toward 10%+ to justify the multiple.

4.4 Tracking Signals

2026F OP ₩10bn+ confirmed in actuals
QD9+ / SD9+ overseas-customer expansion pace
OPM 10%+ maintained
ROE moving toward 10%
2027 earnings estimates starting to print

5. Wirenet (KOSDAQ: 115440) — Momentum Strong, but Market Has Already Discovered It

5.1 Business

Wirenet is a Korean telecom transmission-equipment company. The investment angles: 5G-SA transition, PTN (Packet Transmission Network) demand, transmission-equipment replacement cycle, optional quantum-cryptography exposure.

Hana Securities raised the target price to ₩25,000 in April 2026, with 2026F revenue ₩115.8bn / OP ₩8.7bn and 2027F OP ₩21.7bn.

5.2 Numbers

Item	Value
May 6 close	₩15,810
YTD	+118.1%
20-day return	+41.9%
60-day return	+100.6%
RSI(14)	60.2
2026F revenue	₩115.8bn
2026F OP	₩8.7bn
2026F OPM	7.5%
2026F P/E	23.7×
OP growth	+358%
20D foreign	-₩6.5bn (net sell)

5.3 The Problem: Already Up +118% YTD with Foreign Net Selling

On numbers alone, Wirenet is attractive. OP growth +358% and 2027F OP ₩21.7bn make the current price defensible. Hana’s ₩25,000 target implies +58% upside.

But the market has already discovered it.

YTD +118.1% → already more than doubled
60-day +100.6% → doubled in two months
20D foreign -₩6.5bn → foreign capital is exiting

Hana’s target headroom is large. But this name isn’t a “quiet undervalue” — it’s a “discovered, high-volatility equipment-cycle name.” Quarterly results can swing materially with 5G-SA order timing and transmission-network replacement cadence; chasing into weak foreign flow carries elevated risk.

5.4 Tracking Signals

2026F OP ₩8.7bn confirmed in actuals
5G-SA core network forward-deployment order timing
Foreign net-sell pace easing or reversing
₩14,300–15,000 holding as support (on pullback)

6. Three-Name Comparison — Which Is the Most Structural

Item	QRT	BCnC	Wirenet
Business	Semi reliability validation	Semi consumable-parts localization	Telecom transmission equipment
Thesis character	Structural bottleneck	Materials localization	Project momentum
YTD	+42%	+33%	+118%
2026F OP	₩10.8bn	₩10.9bn	₩8.7bn
2026F P/E	33.3×	42.0×	23.7×
ROE	(unconfirmed)	6.4%	(unconfirmed)
20D foreign	+₩210m	+₩3.97bn	-₩6.5bn
Core strength	AI / RF / space expansion, bottleneck business	Materials localization, customer expansion	5G-SA, quantum-crypto option
Core weakness	P/E 33× burden	P/E 42× + low ROE	Up +118% already, weak flow
Priority	#1	#2	#3

QRT ranks #1 because of the structural multi-vector thesis. AI, HBM, CXL, RF, space — every vector lifts validation demand. The thesis isn’t bet on a single direction; it’s bet on multiple directions simultaneously.

BCnC has a strong materials-localization story, but P/E 42× × ROE 6.4% means price has run ahead of earnings. 2027 earnings leverage has to print materially stronger than 2026 for the current multiple to look fair.

Wirenet has the strongest momentum, but the market has already discovered it. YTD +118%, 20D foreign -₩6.5bn. Closer to event-trade than core-add territory.

7. What the Screen Teaches — Alpha Lives After the Screen, Not In It

7.1 67 Names Found, Most Already Moved

This is the most important screening lesson. “Earnings explosion” is a powerful condition, but the market also knows the condition. Semi equipment, AI materials, energy-transition names — those already in leadership themes already cleared the screen, and those names already moved.

7.2 FnGuide Demonstrates the “After-Discovery” Regime

FnGuide’s January P/E 10× was the alpha zone. May P/E 38× isn’t. If you’re finding a name via screening when its P/E is already 38×, that’s the market’s output, not the screen’s output.

7.3 Alpha Lives in “Speed-of-Discovery vs Gap-Still-Remaining”

Buying all 67 isn’t meaningful. You have to find the names the market hasn’t fully discovered yet — and then distinguish “discount-for-reason” from “simple inattention.”

QRT — "semiconductor validation" hasn't been claimed as a theme yet
 → closer to "simple inattention"
 → re-rates when the category gets recognized

BCnC — materials-localization story is known, but ROE is low
 → closer to "discount-for-reason"
 → discount unwinds when ROE rises

Wirenet — already discovered, +118% YTD
 → closer to "discovery complete"
 → further alpha requires strong confirmation of the priced narrative

That distinction is the actual analytical work after the screen.

8. Two Honest Caveats

8.1 All Three Names Are Up +40 to +50% in the Last 20 Days

QRT +50.5%, BCnC +44.1%, Wirenet +41.9%. A 20-day move of +40 to +50% means this is not a “buy with full conviction now” zone. Short-term overheating can give way to pullbacks; entry after pullback-and-hold is the cleaner setup.

8.2 Don’t Over-Index on the Screen Output

That 67 names cleared the “earnings explosion” criteria is interesting — but the more important fact is that most of the 67 have already moved. The screen is the start, not the destination. The destination is the answer to “why is this specific name still under-moved?”

9. Tracking Signals — The Next Phase After the Screen

9.1 QRT (#1)

2026F OP ~₩10bn confirmed in actuals
RF / space-bound validation revenue actually printing
OPM 12–13% maintained
₩20,500–21,200 holding as support (on pullback)
“Semiconductor validation bottleneck” emerging as a recognized category

9.2 BCnC (#2)

2026F OP ₩10bn+ confirmed in actuals
QD9+ / SD9+ overseas-customer expansion
OPM 10%+ maintained
ROE moving toward 10%
₩17,000–17,500 holding as support (on pullback)

9.3 Wirenet (#3, Event-Trade Posture)

2026F OP ₩8.7bn confirmed in actuals
5G-SA order timing
Foreign net-sell easing or reversing
₩14,300–15,000 holding as support (on pullback)

9.4 The 67-Name Cohort Overall

Whether the negative-bucket names (Devsisters, Alteogen, Astera Sys, SBS) start signaling turnarounds
Whether YTD +20–50% bucket names (Tech Wing, STI, DI) get post-earnings re-rating after results
Whether QRT replicates FnGuide’s “post-discovery P/E expansion” pattern as an early signal

10. The Single Closing Line

The “earnings explosion” screen returned 67 names. Most have already moved. FnGuide demonstrates the “after-discovery” regime most dramatically — P/E 10× → 38×, +279%. Buying FnGuide today on “earnings explosion” framing is buying near the top.

Alpha lives in “speed-of-market-discovery vs gap-still-remaining,” not in the screen output itself. Among the three under-moved names — QRT (+42%, semiconductor validation bottleneck), BCnC (+33%, materials localization), Wirenet (+118%, already discovered) — the answer to “why under-moved?” is different.

QRT is under-moved because “semiconductor validation” hasn’t been claimed as a market theme. Its structural thesis (“the more complex semis get, the more validation is the bottleneck”) fires across AI / HBM / CXL / RF / space. BCnC’s materials-localization story is known but P/E 42× × ROE 6.4% means price has run ahead. Wirenet at +118% YTD with foreign -₩6.5bn 20D is late-stage momentum — strong but past the discovery stage.

All three are up +40–50% in the last 20 sessions. This is not a “full conviction now” zone — it’s a “wait for pullback or wait for results” zone. The screen is the start, not the destination. The destination is the answer to “why is this specific name still under-moved?”

FAQ — Korean Earnings-Explosion Screen May 2026

Q: How many Korean stocks pass an “earnings explosion” screen for 2026? A: As of May 7, 2026: 67 names cleared the criteria (2025 OP > 0) ∧ (2025 NI > 0) ∧ (2026F OP > 0) ∧ (2026F NI > 0) ∧ (2026F OP growth ≥ +80%) ∧ (2026F NI growth ≥ +80%). More than half of those 67 names are up >+50% YTD.

Q: What is FnGuide and why does it matter as a reference case? A: FnGuide is a Korean financial-data and index infrastructure company. Year-start to May 6, 2026, its P/E expanded from 10× to 38× and total return reached +279%. It demonstrates how the “earnings explosion + low multiple + good business” combination plays out under market discovery — and why screening for such names after the re-rating event is structurally late.

Q: Is QRT (405100) publicly traded? A: Yes — QRT is listed on KOSDAQ under ticker 405100. Its core business is semiconductor reliability validation (testing and analysis services for chip makers and fabless designers).

Q: Why is QRT considered structurally interesting? A: The thesis “the more complex semiconductors get, the more validation is the bottleneck” applies across AI, HBM, CXL, RF, and space-bound chips. Validation demand scales with chip complexity, and validation capacity is hard to scale on a short timeline. QRT is a multi-vector beneficiary rather than dependent on any single product cycle.

Q: Is BCnC (146320) publicly traded? A: Yes — BCnC is listed on KOSDAQ under ticker 146320. It manufactures consumable parts (synthetic quartz QD9 / QD9+, silicon SD9+, ceramic CD9) for semiconductor etch and deposition processes, with a localization-driven margin-improvement thesis.

Q: Is Wirenet (115440) publicly traded? A: Yes — Wirenet is listed on KOSDAQ under ticker 115440. It is a Korean telecom transmission-equipment company exposed to 5G-SA transition, PTN demand, transmission-network replacement, and quantum-cryptography optionality.

Q: Which Korean small-cap is the cleanest “earnings explosion” alpha right now? A: Among the three covered here, QRT ranks first on structural-thesis quality (multi-vector, bottleneck character, capacity-constrained). BCnC ranks second on localization narrative but with P/E 42× and ROE 6.4% the multiple has run ahead. Wirenet ranks third — strong momentum but already up +118% YTD with foreign net selling, closer to event-trade than core-add territory.

Q: Is the 67-name screen output a buy list? A: No. The screen is a starting filter, not a buy list. More than half of the 67 names have already moved >+50% YTD. The actual analytical work is distinguishing “still under-discovered” from “discounted-for-reason” within the cohort.

Q: What’s the single most important lesson from the FnGuide reference case? A: Re-rating from low-multiple to high-multiple compresses future return space. P/E 10× → 38× over five months means today’s price requires the most aggressive earnings estimate to print just to be “fair.” Screening for such names after the re-rating event is structurally late.

This post is research and commentary only, not investment advice. The 67-name cohort, individual estimates (Hanyang, KB, Eugene, Korea IR Council, Hana, FnGuide and others), and FnGuide multiple history are sourced from local DB, sell-side reports, and public materials and reflect analyst inference. Actual results may differ. Short-selling, lending, and program-flow data are not confirmed for the local DB. The analysis may be wrong. Data as of May 6–7, 2026 KST.